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ABSTRACT
This paper examines the use of four different modalities to teach the correct
assembly and administration method to use a naloxone nasal device. Naloxone is a
medication which can reverse an opioid overdose when administered correctly. This
specific device has been used for over a decade, and has been instrumental in opioid
prevention educational programs to bystanders and individuals who use substances
(NMDOH, 2017). Prior research studies utilizing naloxone nasal devices, have included
outcome data collected from programs which train individuals who use opioids, and
distribute the naloxone nasal device (Kerr, 2008). Others have included examination of
curriculum content with participant recall of information from the training (Green, 2008;
Strang, 2008). This study and paper examines two specific portions of an opioid overdose
prevention and response curriculum, how to assemble the device and how to use the
device to administer naloxone on an individual who is overdosing. Four different
educational modalities were examined to determine the most effective.

v

TABLE OF CONTENTS
LIST OF FIGURES ......................................................................................................... ix
LIST OF TABLES............................................................................................................. x
CHAPTER 1: LITERATURE REVIEW ........................................................................ 1
Introduction ..................................................................................................................... 1
Historical Background .................................................................................................... 3
Search and Review .......................................................................................................... 6
Epidemiological Overview ......................................................................................... 7
Literature Review............................................................................................................ 9
Discussion and Recommendations ............................................................................... 19
CHAPTER 2: METHODS ............................................................................................. 24
Introduction ................................................................................................................... 24
Participants .................................................................................................................... 26
Eligibility................................................................................................................... 26
Recruitment. .............................................................................................................. 26
Risks and Benefits..................................................................................................... 27
Scheduling................................................................................................................. 27
Research Design............................................................................................................ 28
Sample Size............................................................................................................... 29
Sampling. .................................................................................................................. 30
Group and Observation Design ................................................................................. 30
Measurement Scales.................................................................................................. 32
vi

Initial Observation. ................................................................................................... 33
Second Observation. ................................................................................................. 33
Curriculum .................................................................................................................... 34
Measurement Tools ....................................................................................................... 34
Minimizing Risk ........................................................................................................... 38
Confidentiality .............................................................................................................. 39
Data Protection.............................................................................................................. 39
CHAPTER 3: RESULTS ................................................................................................ 40
Demographics ............................................................................................................... 40
Prior Knowledge Survey ............................................................................................... 43
Observation Sessions .................................................................................................... 44
Analysis......................................................................................................................... 54
Post-Observation Exit Survey ....................................................................................... 61
CHAPTER 4: DISCUSSION ......................................................................................... 64
Curriculum .................................................................................................................... 64
Study Limitations .......................................................................................................... 68
Conclusion .................................................................................................................... 70
APPENDICIES ............................................................................................................... 73
APPENDIX A: CONSENT TO PARTICIPATE IN RESEARCH FORM ................. 74
APPENDIX B: DEMOGRAPHIC SURVEY QUESTIONS ....................................... 76
APPENDIX C: PRIOR KNOWLEDGE SURVEY ..................................................... 77
APPENDIX D: WRITTEN EDUCATIONAL MATERIAL USED IN THE STUDY
vii

........................................................................................................................................... 78
APPENDIX E: OBSERVATION CHECKLIST .......................................................... 79
APPENDIX F: EXIT SURVEY ..................................................................................... 80
APPENDIX G: SCRIPTS FOR EDUCATIONAL SESSIONS – FIRST SESSION . 81
APPENDIX I: 20 MINUTE EDUCATIONAL CURRICULUM ................................ 83
APPENDIX J: OBSERVATION FREQUENCY TABLES FOR TIME TO
DEMONSTRATE ASSEMBLY AND ADMINISTRATION ....................................... 84
Observation 1 – Assembly Time ................................................................................... 84
Observation 1 – Administration Time ........................................................................... 85
Observation 2 – Assembly Time ................................................................................... 87
Observation 2 – Administration Time ........................................................................... 90
APPENDIX K: RESPONSES TO EXIT SURVEY OPEN-ENDED QUESTION –
“DO YOU BELIEVE INFORMATION ON NALOXONE IS HELPFUL?” ............ 92
APPENDIX L: RESPONSE TO EXIT SURVEY QUESTION – “WHY OR HOW
DO YOU BELIEVE INFORMATION ON NALOXONE IS IMPORTANT” .......... 96
APPENDIX M: RESPONSES TO EXIT SURVEY QUESTION – “USE THIS
SPAVE TO WRITE ANYTHING ELSE YOU WOULD LIKE CONCERNING THIS
EXPERIENCE.” ........................................................................................................... 100
REFERENCES .............................................................................................................. 102

viii

LIST OF FIGURES
Figure 3.1 Frequency Graph for Participant Year of Birth ............................................. 42
Figure 3.2 Observation 2 - Ability to Administer the Device Correctly ......................... 61

ix

LIST OF TABLES
Table 3.0 Gender Identity………………………………………………………..…….40
Table 3.1 Frequency for Participant Ethnicity………………………………..………..41
Table 3.2 Frequency for Participant Age………..…………………………………..…43
Table 3.3 Questions about Naloxone……………………………………………..……44
Table 3.4 Selection Frequency and Percentages………………………………..……...45
Table 3.5 Frequency Table for Assembly Demonstrations………………………….....46
Table 3.6 Frequency Table for Administration Demonstrations…………..….……..…47
Table 3.7 Frequency Table with Both Successful Assembly and Administration
Attempts…………………………………………………………..……..….48
Table 3.8 Frequency Tables for Observation Counts both Assembly and
Administration...………………………………………………………..…..51
Table 3.9 Frequency Tables for Count Differences Between Observation 1 and
Observation 2……………………………………….…………..…………..53
Table 3.10 Analysis of Variance for Assembly and Administration Times……….........55
Table 3.11 Observation 1 and Observation 2: Assembly and Administration Descriptive
Information…………………………………………………...………….….57
Table 3.12 Analysis of Variance – Both Successful Assembly and Administration
Attempts……………………………………………………………..……...58
Table 3.13 Time to Administer: Unsuccessful Assembly and Administration
Excluded…………………………………………………………..…….…59

x

Table 3.14 Additional Information and Type Reviewed Between Observation 1 and
Observation 2……………………………………………………..….…….63

xi

CHAPTER 1: LITERATURE REVIEW
Introduction
This review examines the literature concerning Overdose Prevention, Naloxone
Use, harm reduction philosophy and substance use to outline the need for naloxone use
education. This education focuses on the ability for laypeople to learn how to use
naloxone in an opioid overdose situation. Included is a focus on programs and policies in
New Mexico since New Mexico was the first state in the United States to allow for legal
distribution of naloxone to individuals using substances (NMSA, 2001). Due to the lack
of reviewed literature in New Mexico it also includes a review of programs and research
conducted outside New Mexico.
Previous research utilized a variety of methods to explore these issues. One
method utilized was a survey of Emergency Medical Providers and their attitudes toward
overdose prevention and naloxone administration programs (Tobin, 2005). This example
helped to determine professional attitudes by utilizing self-administered and anonymous
surveys. Other research has utilized surveys of community members rather than First
Responders and Licensed Providers. The community members often consist of
individuals who inject substances (IIS). These surveys usually involve participants being
asked about individual behaviors and experiences (Seal, 2001).
Another example of data collection is through the examination of pre-existing
records. This includes looking at electronic records for hospital admissions and medical
examiner databases regarding overdose and naloxone use (Vikle, 2003). Within this
process, the researchers gather data through existing databases or patient records and
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search for specific markers. In Assessment for Deaths in out-of-hospital heroin overdose
patients treated with Naloxone who refuse transport, Vilke looked at the refusal of
admission of a patient during EMS provision of services.
These methods are not unusual within the research area of IIS behavior and
response, especially regarding overdose prevention. Since injecting substances is a
personal situation and an individual may be using substances for multiple reasons, selfsurvey is often the best method for collecting data. Utilization of anonymous surveys
helps to increase the reliability for more accurate responses, especially when the surveys
include requests for sensitive information such as substance use (Murdoch, 2014).
Correlating the information collected through anonymous surveys with reports through
hospital emergency rooms, Offices of the Medical Investigator, and other health
institutions helps to validate the information gathered. This is often accomplished
through the utilization of multiple research studies with the cumulative reports showing
the complex picture of substance use and the behaviors of those who are using them.
Many of the surveys utilize incentives to also help increase participation within these
marginalized populations (Murdoch, 2014).
Part of the understanding needed is the examination of the complex issues behind
why individuals use substances. Individuals use substances for a variety of reasons,
including escaping from trauma, problems and the difficulties of life due to different life
situations, such as poverty, homophobia, sexual assault and abuse, and mental health
issues (Kotov, 2010). Substance use may also occur initially due to health reasons such
as injury or pain management, mental or behavioral health treatments, or self-medication
2

for these types of issues (Bailey, 2006). Other factors include social and family norms or
pressures and may be learned directly through the behaviors exhibited by peers or older
family members and result in intergenerational substance use (Bailey, 2006; NIDA,
2006). When examining substance use and overdose prevention, a social-causation
framework is important to utilize while exploring the structure of the medical complex
and how they respond toward individuals using substances and their response to overdose
prevention education.
Historical Background
This review examines the establishment of harm reduction overdose prevention
programs and the response of medical service providers toward these programs.
Specifically, the distribution of naloxone (Narcan) to individuals injecting substances and
their attitudes toward the education of IIS for overdose prevention and naloxone use.
This includes the use of naloxone by EMS in some areas, such as the program developed
in King County, Washington State (Belz, 2006).
This examination and how it connects to the education of individuals regarding
naloxone use is important to understand the continued high rate of overdose deaths in
New Mexico (Shah, 2009). New Mexico has a history of injection heroin use with
intergenerational use reported in different areas of the state, especially rural areas, such as
Rio Arriba and Valencia Counties (SHAH, 2009; NIDA, 2006). In 1997, the New
Mexico State Legislature passed the Harm Reduction Act (NMSA 24-2-1; 1978), which
required the New Mexico Department of Health to establish Harm Reduction and Syringe
Service Programs (SSP) in New Mexico (NMSA 24-2-1;1978). The Act is written in
3

such a way as to make it possible for those who need access to sterile syringes in New
Mexico to have access to them. The initial programs were established and began
operations in February of 1998. (NMDOH, 2017). Additional programs were developed
across the state, and more continue to be added. As of September 2017, the New Mexico
Department of Health lists forty-eight Public Health Office and community partner
locations offering syringe services, some of which include mobile programs in both urban
and rural areas (NMDOH, 2017). Details and contact information for locations can be
found through the website www.nmhivguide.org (NMDOH, 2017).
The next step for the Harm Reduction Program in New Mexico was to address the
high rate of overdose death due to injection heroin use, and other opioid use in
conjunction with advocating the use of safer injection practices and the sterile use of
syringes. To reduce opioid overdose mortality rates, the New Mexico Department of
Health started a pilot program at an Albuquerque drop-in center in 2001 managed by
Albuquerque Health Care for the Homeless (NMDOH, 2017). This program taught a
thorough and detailed overdose prevention and response program directly to individuals
injecting heroin or other opioids. The participants attended a three-hour class covering
issues surrounding overdoses, including: how to prevent an overdose, recognizing an
overdose, what to do in the event of an overdose – rescue breathing and Naloxone
administration, and myths surrounding overdoses. Initially, the participants were provided
with a cash incentive (NMDOH, 2017).
When participants completed the overdose prevention and response training, they
were prescribed naloxone and provided with two (sometimes three or four) doses of
4

naloxone to take home and use if they observed an opioid overdose. As participants used
the naloxone - or if it was lost, confiscated, or expired - they could simply report the
conditions under which the naloxone was used (or lost) and obtain replacements. As the
program continued, the New Mexico Department of Health expanded the locations
offering the training. As of September 2017, the website www.nmhivguide.org now lists
39 Public Health Office and community partner locations offering overdose prevention
education and naloxone. This includes some providers who travel directly to participants
and teach them in their homes or in other local or community spaces (NMDOH, 2009;
NMDOH 2017).
Another important factor in this history is a curriculum change in 2005. The
program had shortened the training from the original three-hour class to a 15-20-minute
format more suitable for dissemination on the street. This shorter curriculum enabled the
class to be offered outside of a classroom or group room setting. It has been received well
by participants since it also enables them to participate at locations of their choosing and
comfortability, including outreach sites, motel rooms, at home, and at public health
offices and other community providers.
This change in the program from the three-hour to the 15-20-minute format
enabled higher numbers of participants to be trained. As of March 21, 2009, 5131
participants had been trained and 1589 reports of Naloxone being used had been recorded
(NM-DOH:2009). In calendar year 2015 alone, there were 2459 individuals trained, and
749 reversals reported, a 30.45% usage rate (NMDOH 2017). The program has been
successful in reaching participants, however the overall rates of overdose fatalities has
5

remained at a high level, with a national ranking of eight in the US in fatal overdoses
(Rudd, 2016).
One of the improvements for the change from the 3-hour training to the brief
intervention was the ability to more easily ensure fidelity regarding curriculum delivery.
Since it was a shorter educational session, it became easier to keep participants’ attention
through the educational session. The importance of stressing fidelity in substance use and
overdose prevention education is twofold: It reduces cognitive overload and confuse
surrounding the issues presented, and helps increase peer reinforcement of the
information since the same information is provided to each participant in the classes
(Dusenbury, et. Al., 2003; Abbot, 1998).
Search and Review
To conduct a search of the relevant databases, the libraries at the University of
New Mexico Main Campus and Health and Science Library were utilized. The search
extended for a 20-year span of time from 1997 to 2017 to capture possibly relevant
articles. With one exception, the articles included were from 1998-2017. The article from
1997 was included as additional background material. The databases utilized in the search
included medical, educational, and sociological. These databases included Web of
Knowledge, EBSCO, PubMed, Ovid, and ERIC. Search words included “overdose,”
“naloxone,” “Narcan,” “heroin,” “injection drug use,” and “syringe exchange.” In
addition, other articles are included which did not appear in the main searches. These
were obtained through searches of government reports or correspondence with
professionals in the field of harm reduction and are from peer-reviewed journals or
6

government agencies. They include information about epidemiology or program
operations. Since most overdose prevention programs with naloxone distribution are
managed or overseen by harm reduction agencies or government organizations, this
makes the inclusion of these articles and reports relevant to the background and
supporting information for this paper. Additional articles on education using
manipulatives, or demonstration items are included as well as an article on using simpler
language to educate individuals regarding medical devices (Bittner, 2016).
The review focused on articles which examined attitudes towards overdose
prevention and syringe exchange programs. Articles were sorted into Primary, Secondary
and Tertiary articles and into supporting documents. The Primary articles include those
focusing in three areas: direct education, participant surveys, and medical database
collection. These are important since they show the direct attitudes of individuals
injecting substances and medical personnel, which shaped the development of the
curriculum. The Secondary articles are those which examine programs and report on
their results. These articles are as important as the Primary articles, but because the
primary focus of this review is education and use of naloxone, they are relegated to a
secondary position. The Tertiary articles are supporting documents which highlight
programs and provide supporting data or information, such as reports from the New
Mexico Department of Health (NMDOH) and the federal Substance Abuse and Mental
Health Services Administration (SAMSHA).
Epidemiological Overview. An epidemiological overview and profile is
important to this study since it provides some of the background to the importance of
7

naloxone use. According to the New Mexico Department of Health Harm Reduction
Program Year Ending Report for 2008, there were 1271 new participants enrolled in the
Syringe Exchange Programs, and 1482 participants re-enrolled. In addition, there were
almost 2.8 million syringes exchanged. There were 750 new patients enrolled in the
Overdose Prevention program, and 302 Records of Naloxone Use reported. The rate of
unintentional overdoses saw a slight decline from 1998, but began to rise again in 2006.
The rate of overall unintentional overdose deaths was 19.6 per 100,000 in 2008 (Shah,
2009). Specifically, the rate of heroin/illicit opioids related overdoses in New Mexico
rose to the second highest level in 2008 at an observed rate of 7.4 deaths per 100,000
(Shah, 2009). In 1998 the rate was 7.6 deaths per 100,000 with regard to heroin (Shah,
2009). This snapshot of rates in 2008 is important to see the trend in NM. According to
the NMDOH Substance Abuse Epidemiological Profile issued in 2016, the total opioid
overdose mortality rates in 2010-2014, had changed to 20.4 per 100,000, with the
heroin/illicit death rate at 7.84 per 100,000; prescriptions at 9.6 per 100,000; and, a
combination of both heroin/illicit and prescription opioids at 3.0 per 100,000 (NMDOHERD, 2016).
With this epidemiological profile in mind, the NM Department of Health tries to
reduce the mortality rates of opioid overdoses, particularly heroin overdoses, by targeting
those who inject opioids. In addition, other people in the lives of those who inject opioids
are also targeted by the program, often referred to as “bystanders.” This population is
provided with training programs on overdose prevention and the distribution of naloxone.
In 2006, originally due to a change in manufacturing, the naloxone being distributed
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through these programs changed from using an injection delivery system (pre-loaded
vials attached to syringe barrels and then injected into overdosing individuals) to an intranasal delivery method. Since the introduction of the intra-nasal method, more noninjectors (bystanders and people using opioid pills) seem to be more comfortable with
using naloxone, although this is only anecdotal at this time. This is important because of
the eligibility of bystanders to receive the training and obtain naloxone. This allows for
others who may be able to respond faster than EMS (especially in rural areas) to be
trained and able to respond appropriately.
In 2016, the NM State Legislature passed two bills, SB 262 and HB 277 which
were then signed by the Governor on March 4, 2016 (NMDOH, 2017). These bills
expand accessibility to naloxone by allowing statewide standing orders to be issued.
These standing orders allow for pharmacists, programs registered with the NMDOH, and
programs or individuals operating under a Licensed Prescribers Standing Order to
distribute naloxone without a prescription (NMSA – 1978, Section 24-23-1, 2016). This
increase in ability for programs to distribute naloxone overcomes an important barrier of
having programs resident in only a select few agencies or locations (Burris, 2009).
Literature Review
An article by Nicola S. Oldham and Nat M.J. Wright on A UK Policy on 'take
Home Naloxone' for Opiate Users – Strategy or Stalemate? is important because it is the
only review article found about policy regarding naloxone take-home doses. Oldham and
Wright reviewed 11 different articles while focusing on the issue of take-home doses,
including information from New Mexico in 2002 (personal communication from
9

Maureen Rule: 2002). There were only two arguments presented regarding concerns
when take-home doses are provided to participants in the educational program. The first
was the concern for the potential to encourage solitary substance use; the second was the
concern for the possibility users would mistakenly administer naloxone for any substance
overdoses, rather than just for opiate overdoses. This second concern is based in part
because naloxone has no effect with regard to non-opioid substances. The article
concludes overdose prevention and response programs are cost-effective, and when
utilized as part of a comprehensive educational program, and naloxone distribution is not
seen by participants as encouraging solitary use or able to be used for all substance
overdoses. With these findings, the report concluded naloxone needs to be distributed to
help participants, and it indicated further studies should be conducted done through
clinical trials (Oldham, 2003).
Intranasal Naloxone for the treatment of suspected heroin overdose by Debra
Kerr, Paul Dietze and Anne-Maree Kelly was published in 2007 and identified fifteen
articles during the review process, but deemed only seven to be relevant. The author
sought articles specific to intra-nasal naloxone delivery methods. Since this method of
delivery was fairly new at the time of publication, the article concluded there was not yet
enough evidence to prove the effectiveness of intra-nasal delivery over intra-muscular
delivery of naloxone, and additional research is needed for front-line EMS or hospital
workers. However, it appears to be effective, and should help reduce accidental
needlesticks when used in community based or peer-based training and administration
programs (Kerr, 2007). Since this publication, there has been further examination of the
10

use of intra-nasal delivered naloxone, which has shown it to be effective (Walley, 2017).
Among the other Primary references, the articles consist mostly of information
gathered through surveys of participants in programs, including individuals using
substances, as well as an article specifically about youth injectors and their low rates of
injection risk behavior. This article shows younger injectors (15-30) were less likely to
engage in riskier injection behavior (Hagan, 2007). Younger injectors also self-reported
only 15% used injection equipment previously used by another injector (Hagan, 2007).
The same study examined 5 different US cities, and arrived at the conclusion that while
some of the younger injectors would inject alone, this behavior provided both some
protection and some risk. The participants felt protected because there was less chance of
them being jumped or rolled while they were using. The risks the participants
encountered involved the problems associated with overdosing while alone, and not being
discovered in time to have the overdose reversed (Hagan, 2007).
Elizabeth Maloney, et al, proposed the conclusion of older injectors being more
likely to overdose, and older opiate users were even more likely to overdose than those
injecting other substances. The article also concluded accidental overdoses are clearly
different than suicide attempts through overdose, and should be treated separately,
including with training and education programs (Maloney, 2009).
However, another article about the predictors of overdoses, explored how there
was an independent correlation of younger injectors to be more likely to overdose (Seal,
2001). In part, this survey was done in 2001 before there were widespread training
programs for individuals injecting substances, since the first legal program had just begun
11

in NM in 2001 (NMDOH 2017), whereas the previously mention article is more recent
and takes into account the prevalence of overdose prevention programs (Hagan, 2007).
Another report showed individuals who injected opiates and were trained in a
comprehensive overdose prevention program had successful rates of overdose reversals
(Doe-Simkins, 2009). In the study, Saved by the Nose: Bystander-administered
intranasal Naloxone Hydrochloride for opioid overdose, there were 385 participants
enrolled over a 15-month period. During follow-up observations, 50 of these participants
had used Naloxone to reverse an overdose on 74 separate occasions (Doe-Simkin, 2009).
The participants also reported very few problems when administering the naloxone. Even
though two of the participants stated they had difficulty in assembling the atomizer to the
barrel, both were able to successfully reverse the overdose through either injecting the
naloxone in one case and utilizing rescue breathing in the other until help arrived (DoeSimpkins, 2009). This is important as it indicates willingness to determine methods for
reversing overdoses, and the necessity for educational programs to be more
comprehensive and to include more than just naloxone administration, such as other tools
including rescue breathing or alternative delivery methods for naloxone. Another
important component in educational curricula is overdose prevention. Ensuring the
language used when providing education on medical devices is as simple as possible and
appropriate to the level of education and competence of the students can also make a
positive impact (Bittner, 2016). If the curriculum itself is not in simplified language, then
having the medical providers or educator translate the information from medical or
scientific language into more commonly spoken language helps to increase the facility of
12

the provider to communicate with the patient (Bittner, 2016).
Overdose training and take-home Naloxone for opiate users: prospective cohort
study of impact on knowledge and attitudes and subsequent management of overdoses,
was completed in the UK surveying individuals injecting opioids after training them in
overdose prevention and naloxone administration and providing them with take-home
naloxone. This study examined at the information participants retained after the
educational session. They recruited 239 people who use opioids from 20 different
facilities in the UK. Prior to the educational sessions, the participants were given selfassessment surveys to complete regarding their current knowledge of overdose
prevention and response. They were then trained in overdose prevention and response.
To see if there were changes in attitudes or knowledge, a follow-up was then
administered after the educational session. There were definite changes in knowledge
according to the study, specifically, an increase in the number of participants being able
to explain overdose risk-factors from just under 1/3rd to almost 2/3rds of the participants.
After the training, almost all the participants stated they felt comfortable in using
naloxone in an overdose situation, and 28% of those trained subsequently trained others
how to use naloxone (Strang, 2008). However, these observations were conducted
immediately after training, and there was not any delay in the administration of the postsurvey. Had there been an additional follow-up survey conducted at a later time, it might
have allowed the researchers to determine if there was any encoding in long-term
memory based on how many participants retained and recalled the information.
An article written in 1999 examines the attitudes of participants in safer injection
13

rooms (SIRs). This is important since it explores some of the professed attitudes in a
slightly different setting than the current syringe service programs in the United States,
and utilizes data collected from participants regarding past overdose experiences.
Establishing safe injecting rooms in Australia: attitudes of injecting drug users by Craig
Fry, Sandra Fox and Greg Rumbold shows the willingness of individuals who inject
opioids to use safer injection rooms. This behavior was reported in part because of their
higher likelihood to overdose, and having a place where they might be safer in the event
an overdose did occur. “Turning Point study participants who were willing to use SIRs
were more likely to be male, have experienced more non-fatal heroin overdoses and used
heroin more frequently in the past six months compared to those people were not willing
to use SIRs.” (Fry, 1999) This shows the importance of expanding overdose prevention
programs, due to the recognition by participants of their need for help, and the presence
of an attitude of accepting the help available, and showing how participants will ask for
the help they believe they need (Fry, 1999). This attitude shows promise and reveals
participants understand their situation and want to improve their quality of life (Fry,
1999). Understanding how participants want to improve their lives is important. It speaks
to the desire to be in a safer or better place, and so when someone recognizes a danger,
they are more willing to learn how to prevent or change the level of risk if there are
options available.
Another important aspect of naloxone and overdose prevention education is how
naloxone is used through Emergency Medical Services (EMS). Naloxone use in a tieredresponse Emergency Response Services system, reviewed the response of EMS in 164
14

cases where naloxone was administered during a call. The results showed a full response
in 78 patients, a partial response in 41 patients, no response in 24 and none recorded in 21
(Belz, 2006). This demonstrates the effectiveness of naloxone when it is administered,
and how most patients responded, with the naloxone reversing the effects of the opioid.
An interesting portion of this article is the inclusion of adverse reactions to naloxone.
These reactions included the patient waking up and being violent (due to the naloxone
forcing them into withdrawals). They also included other bodily reactions such as
vomiting. “This occurred in 25 of the cases (15%)” (Belz, 2006). This is particularly
interesting since this is not often recognized or mentioned in other studies or articles. It is
important to realize these reactions are not unusual as they are symptoms of withdrawal,
which can be an unpleasant experience, including vomiting, aching muscles and joints,
restlessness, and anxiety. So, the violent reactions reported rarely may be attributed to
someone suddenly waking up and not understanding what is happening around them,
while having multiple people “hovering” around them – possibly EMS or law
enforcement – causing additional anxiety or fear.
Another article about EMS focuses on the attitudes of EMS providers and it used
an anonymous survey sent to EMS providers. In Attitudes of Emergency Medical Service
Providers toward Naloxone distribution programs by Karin Tobin, et al, 54% of the
respondents indicated a belief naloxone distribution programs would not be effective and
revealed the misperception of individuals who injected would not be able to take the
proper steps to reverse an overdose because of lack of training and experience with
administering naloxone or rescue breathing (Tobin, 2005). Some of the other concerns
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centered upon the perceptions of participants who had naloxone would have a false sense
of security, and thus would be more likely to overdose, and indicated the program
condoned substance use. The other major concerns expressed were theft of naloxone from
those trained and how naloxone use would increase the number of used syringes in the
community. As the authors point out, this information on behalf of the EMS providers
was mostly gleaned from newspapers or other media, as well as co-workers, and not
through training or intimate knowledge of a naloxone distribution program (Tobin, 2005).
In Assessment for Deaths in out-of-hospital heroin overdose patients treated with
Naloxone who refuse transport, Gary Vilke (et. al.) records in San Diego were
retroactively examined to see how many patients did not get transported to hospital or
other medical settings after being treated with naloxone by EMS providers. Over the
five-year study time-frame, there were 8,366 patients given Naloxone, and 998 refused
transport or 11% of the total patients (Vilke, 2003). During the same time-frame, the
Medical Examiner (ME) database in San Diego lists 601 deaths because of
morphine/opiates. After matching the demographics and other identifiers between the
two datasets, it showed that none of the 998 patients who had refused transport were
listed within 12 hours in the ME dataset. This comparison of the two datasets shows the
naloxone appears to have been successful in averting the death of the 998 patients. The
biggest limitation in the study is it did not continue with follow-up in local medical
facilities to see if any of the released patients sought treatment after their release. One
question which could possibly be explored if some of the patients were able to be
surveyed is whether those who refused transport did so because they had other
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mechanisms to ensure they did not have a repeat overdose experience within the next 12
hours.
To further show how intranasal administration of naloxone is an acceptable and
effective method of delivery when compared with the intravenous (injectable)
administration of naloxone, Intranasal Naloxone is a viable alternative to intravenous
Naloxone for prehospital narcotic overdose, by Tania Robertson, Gregory Hendley, Geoff
Stroh, and Marc Shalit compared these two methods. This was done through a review of
the use of intranasal and intravenous naloxone through retrospective EMS data records in
Denver, Colorado. The results showed the use of intranasal naloxone took longer to
visibly take effect, but was a useful and effective alternative (Robertson, 2009). The
limitations of the study were mostly due to missing data points because it was a
retrospective study rather than a designed and implemented research project. Another
possibly confounding factor the researchers discovered was how some of the overdose
cases included may have been misidentified when they were not actually opioid
overdoses, again, due to the retrospective nature, this was a difficult item to discover.
Overall, the study was not invasive to participants since it utilizes existing data. This can
also be important as many studies may not take into account the sensitive nature of
surveying participants about a sensitive subject such as their experiences with overdoses
and history of responding to others who overdose.
The next set of studies show correlative data, but are not direct studies of
participants, or are not as direct in the discussion of overdose prevention. For example,
there is an article by Lee S. Friedman on the surveillance of overdoses utilizing poison
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control data. It describes the problems of overdoses, and focuses more on fentanyl than
on other opiates. It is important because it shows the increase in opiate overdoses from
160 calls in 2002 to 213 calls in 2007 (Friedman, 2009). This trend of increasing
overdoses has continued and has been documented in New Mexico thoroughly through
the New Mexico Department of Health Epidemiology and Response Division, which
reports between 2010-2014, there was a 46.3% increase in ER visits due to opioid
overdoses (NMDOH, 2016).
Integrating programs with a philosophical basis in harm reduction is important to
ensure success of these programs. For example, Hickman, et. al. present information
about prevalence of injection drug use in 3 UK cities, and supports the information
proposing syringe exchange programs need to be expanded, including programs
integrating overdose prevention, citing a 2% overdose mortality rate (Hickman, 2004).
Additionally, with hepatitis C infection rates among individuals injecting substances also
shows support and the importance for the inclusion of supplemental services such as
overdose prevention, HIV services, adult viral hepatitis prevention, and vaccination
services improves the overall program and continuity of care participants receive
(Holtzman, 2009; NMDOH 2017).
What is not represented in the literature is an evaluation of the methods used to
teach individuals how to use naloxone. This is a significant absence in the literature, and
one which this study proposes to begin to rectify. While there is more information about
effectiveness and response for EMS training (David, 2014), little has been done to show
effectiveness for bystanders. This is an important gap to note since programs have
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traditionally been centered on bystanders, especially those who inject substances
themselves, or those who are around them on a regular basis, including family and
friends.
Discussion and Recommendations
An interesting portion of the articles included was in most cases, opiate overdose
rates continue to increase in most places, despite prevention and distribution programs.
All the articles which discuss prevention and distribution programs agree comprehensive
programs need to involve preventative measures, recognition (what is an overdose), what
to do if there is an overdose, calling 911 (EMS), how to use rescue breathing, how to
administer naloxone (Dark, 1997; Sporer, 2003; NMDOH, 2017), and may include
information on what myths abound regarding how to respond to an overdose (NMDOH,
2017). As an example, in the NM program, the group leaders teach using a sternal rub to
try and stimulate someone awake out of a heavy nod (non-responsive state, but still
breathing more than 12 breaths a minute, the minimum necessary breathing rater).
Participants will answer with their ideas about how to reverse an overdose, such as using
ice in the groin area. Unfortunately, while this may shock an individual awake, more
likely it will cause the individual's blood to cool even more through the femoral artery,
and send the individual into a hypothermic-like state. Similar remedies such as injecting
the individual with saline or another substance are also present in the common
misinformation passed from one person to another. This indicates the importance of
prevention programs to provide information on why these activities do not actually help,
and often may hurt the individual. This information is reflected as best practices by the
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Substance Abuse and Mental Health Services Administration, as seen in their Opioid
Overdose Prevention Toolkit, revised in 2016.
In addition to participant education, the information needs to be provided to
bystanders. This includes family members, partners, neighbors, other relatives, or friends.
Anyone who is around the person who is using opioids. It is important to remember an
individual who is overdosing is not giving themselves naloxone. Someone else must be
present to administer it to them. Elliot W. Eisner (1994) states in Cognition and
Curriculum Reconsidered, “The task of deciding what to teach is ultimately related to a
vision of human nature and an image of the purposes of schooling” (p. 12). In the case of
overdose prevention, this involves ensuring the bystander can recognize an overdose, and
respond accordingly.
Because there is not much research on the naloxone device itself, other medical
devices, such as inhalers, and how patients are taught to use them becomes an important
guide. One of the results of this education is regardless of the type of instruction
provided, the proper use of the inhaler diminishes over time (Ovchinikova, 2011). To
bolster this, the education should be repeated on a regular basis (Ovchinikova, 2011).
Since there has not been research on this regarding naloxone devices, it is one of the main
questions of the effectiveness of the curriculum if it is only presented one time and not
repeated.
Another problem not addressed in the literature is the fear many who use opioids
have of being arrested if they call EMS for an overdose situation. In New Mexico, the
state legislature passed the Good Samaritan 911 Law which took effect in June of 2007.
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The law states an individual calling 911 is exempt from arrest or citation, even if they are
using or currently high except in certain circumstances such as an individual with
outstanding warrants or if there is obvious intent to distribute illicit substances. There are
no data available to see if it is having an effect, however, there has been some anecdotal
reports to the NMDOH where individuals have stated they did call 911 after they found
out about the Good Samaritan Law through the overdose prevention training. These
same individuals have also reported they did not feel harassed by law enforcement
(NMDOH, 2009). While data on this has never been compiled due to the complexity of
gathering it from individuals who do not call EMS, it is an important factor to consider
from the standpoint of decreasing stigma.
Recommendations for programs include ensuring the comprehensiveness of the
prevention program, and as much as possible having the classes as peer education classes,
where other people who have used substances are the moderators or instructors for the
class (Strang, 2008). This helps to lend more credibility to the class, especially when
discussing issues around myths to revive overdosing individuals. It is also important,
regardless of the moderator/instructor, the class be approached from a non-threatening
and non-argumentative stance. Participants should be made to feel they are a part of the
class, and not being lectured. This helps to build their own self-efficacy and self-esteem.
Also, participants in the class need to practice the procedures. Having individuals be able
to manipulate the device, practice with it, and to go through the steps of the plan the
person has developed in order to respond to an overdose is essential. The steps for rescue
breathing should be demonstrated, and each participant should practice how to perform
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rescue breathing in as realistic of a setting as possible. The administration of naloxone
should also be demonstrated and then practiced, including assembling the device if it is a
device which needs assembly. This helps to reinforce the process for the participants,
especially participants who may not believe they learn through listening, but through
doing. Participants should also be given written materials in their primary language
whenever possible. This again helps reinforce the information, and gives the participants
a “cheat sheet” if they find themselves responding to an overdose (Abbot, 1998).
When overdose prevention programs first started, medical providers did not
believe individuals who inject substances would be able to correctly administer naloxone
or to be able to perform procedures such as rescue breathing (Tobin, 2005). However, it
has been demonstrated how participants can indeed perform these procedures and
administer naloxone appropriately (Oldham, 2003). In support of this, in New Mexico,
2,459 new individuals were trained in overdose prevention, including the use of
naloxone; 769 individuals self-reported having successfully used naloxone on another
person. So, 31% of the number of people trained to use naloxone were able to
successfully reverse an opioid overdose in 2015 (NMDOH 2017). It is important to show
there is a difference in how the behaviors are seen by individuals who inject, emergency
response personnel, medical professionals, and the general public. It is also important to
understand how changes have occurred over time as prevention programs have begun to
proliferate, evidenced by the comparison of earlier studies showing younger injectors
being more at risk for fatal overdoses (Seal, 2001) to more recent studies (Walley
2017).With overdose prevention programs expanding, it has changed behavior and now it
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is more likely for older individuals to have fatal overdoses and younger injectors to have
fewer fatal overdoses due to increased availability and education on information about
prevention and how transmission of behaviors from older to younger injection drug users
occur, especially within families and social support groups (Hagan, 2007). This is part of
why it is important for prevention programs to be available not just for individuals who
inject heroin and others using opioids, but also for their families and bystanders (Hagan,
2007).
The historical perception of the treatment received by individuals using substance
impacts the rate which injectors contact EMS, compounded with the fears of being
arrested, cited, or harassed by law enforcement, this results in some individuals not
seeking help (Tobin, 2005). This also is the case with individuals not wanting to go to
hospitals or medical facilities due to the manner they are treated. For example, they often
report having heard things such as “you're just a junkie.” This is a detriment to the
participant's self-efficacy and self-esteem, and is a part of why it is so important for
participants to be so involved with their own education in overdose prevention
(NMDOH-2009).
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CHAPTER 2: METHODS
Introduction
This study seeks to discover whether the mode of presentation when educating
individuals about the usage of a common naloxone delivery device affects the proficiency
of assembly and administration of the naloxone. Some have argued education is not
needed for people to understand how the naloxone device is used on someone who is
overdosing. Others have required lengthy education and training sessions (NMDOH
2017). It has been presented by at least one outcome study of overdose prevention
education (Doe-Simkins, 2009) the utilization of shorter interventions with minimal (1520-minute) education is needed for individuals to be able to correctly assemble and
utilize the naloxone device in overdose situations. Others have stipulated longer training
sessions including detailed instructions and practice time with the naloxone device
(Coleman, 2015) regarding how the device is assembled and the medication administered
(Green, 2008; Walley, 2017), or incorporated into other trainings, such as the American
Heart Association Incorporating naloxone assessment and possible use into the
emergency response procedures (Walley, 2017; Lavonas, 2015). However, with the
increase in types of programs, the training is not standardized nationally (Green, 2008;
Walley, 2017). Also, there are more options available for naloxone delivery in the past
two years (2015-2017), some of the older methods are preferred by some programs and
participants because they are familiar with them. This has resulted in debate on which
devices are more likely to be used in overdose situations. The idea of individuals being
motivated to use naloxone to reverse an overdose becomes more complex when there are
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perceived barriers to the education of individuals and to obtaining naloxone (Ellison,
2016). This can include the length of time it takes to sit through an educational session. It
is important to understand the capacity of someone to learn the assembly and usage of a
naloxone device. In addition, it is important to understand how much of the information
is retained based on the amount and complexity of the education provided. In a 2015
study, participants noted the importance of being able to handle or practice handling and
assembly of the device (Coleman, 2015). This retention of information could then be a
factor in the comfortability of and individual to use naloxone, thus improving the chances
of reversing the overdose.
The main hypothesis for this study is it is more effective to utilize an in-person
demonstration and education modality to teach individuals how to assemble and
administer intra-nasal naloxone. This includes the encoding and recall of the information
in order to more effectively use the device successfully. After the educational
intervention, an in-person educational modality will allow an individual to recall how to
assemble and utilize the naloxone delivery device quickly enough to reverse an opioid
overdose. By showing the effectiveness of this modality, it will help determine how much
information and the type of education individuals need to be able to successfully recall
how to assemble and utilize the naloxone delivery device at a later time. This will help
determine if the information is received in both working memory and encoded in longterm memory. It will also help to determine if there is a certain level or amount of
education required to encode the information in long term memory.
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Participants
Eligibility. The study had only one eligibility requirement. The requirement was
the ability to fluently read and understand English. Because this educational intervention
focused on individuals who are naïve to information about how to utilize naloxone, it was
beneficial for the majority of participants to have not had prior knowledge of using
naloxone. However, because some individuals were expected to have heard of naloxone
previously, or may have had previous experience using naloxone, or having received
instruction on its’ usage, a survey was utilized to determine the extent of the prior
knowledge or experience. This also helped to provide some comparative data.
Recruitment. The participants in this study were students at the University of
New Mexico, recruited through the UNM College of Education, Educational Psychology
Research Pool. Students in the “Pool” are mostly juniors and seniors, although some are
freshmen or sophomores. All of the students are enrolled in Educational Psychology
courses 303 and 310 at the time of their participation in the study. Participating in a
research project is a requirement of their coursework. Students also have an alternative
option to being in a research study by writing an analysis of a research journal. No
individual was coerced or required to be in the study, it was their choice to participate. By
drawing subjects from this pool of students, it allowed for a cross-section of different
ethnicities and experiences related to substance use.
Another advantage for utilizing students from the Educational Psychology
Research Pool was the ability to have them return for follow-up observations. Had the
study utilized other members of the community or other populations, it could have
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resulted in low return rates for follow-up observations. By utilizing the Pool, this ensured
there was enough of a return rate, and ensured there was a stable population, which was
important in this situation to be able to have enough participants to complete all
observation points of the study.
Risks and Benefits. This study posed minimal risk to participants. The main
perceived benefit to the study centers around individuals in the study having the
opportunity to learn how to use naloxone to reverse opiate overdoses. This may have
been an opportunity not otherwise available to the participants, since they may not have
perceived the importance or educational need until an overdose situation occurred in their
own lives, either to themselves or to another person close to them. So, by participating in
the study, the participants gain some additional education and tools to be able to respond
in an overdose situation.
Scheduling. The participants scheduled appointments by selecting times provided
on an online calendar system. Confirmation of appointments were conducted through the
UNM email system to keep it secure and private. Each initial appointment included the
participant completing the Consent Form (Appendix A) Demographic survey (Appendix
B) prior-knowledge survey (Appendix C), educational intervention (Appendix D), and
the first observation demonstration (Appendix E). Participants were scheduled in 30minute intervals for the initial appointment, with up to 5 individuals scheduled for a
specific time (based on the number of research assistants scheduled). Follow-up
appointments for the second observation and completion of the post-survey (Appendix F)
were schedule for two weeks following the initial appointment.
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Participants were informed of the second (follow-up) observation appointment
when they scheduled the initial appointment. They were reminded at the conclusion of
the first observation appointment and provided with a return appointment card. A
reminder email was also sent to each participant 48-72 hours prior to their scheduled
time. The second session was scheduled in 15-minute intervals and consisted of the
participant observation and the post-experiment exit `survey. All participants were offered
the full overdose prevention and response training at the end of the second observation
session. When a participant elected to receive this educational session, it was conducted
by a New Mexico Department of Health Certified Harm Reduction Specialist to ensure
each participant received the standard education utilized in New Mexico for the past
decade (NMDOH, 2017). This time commitment was not included in the 15-minute
second observation appointment; however, participants were advised of this additional
time in the Consent Form (Appendix A) and in the reminder emails for the second
observation appointment. Any participant who elected not to go through the educational
session was provided with a written copy of the curriculum.
Research Design
This study included a participant survey on demographics and prior-knowledge
survey questions inquiring into possible motivation for wanting to learn and remember
the information presented within the educational intervention and possible information
already known about naloxone. The initial intervention utilized four different group
assignments indicating which educational modality the participant received. Participants
in each group received one of four different modalities of education on how to assemble
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and utilize (or administer) naloxone. Each session was conducted individually with the
participant. These four different educational intervention modalities included: 1) no
education provided; 2) written directions for assembly and use; 3) a video showing how
the device is assembled and used; and finally, 4) an in-person demonstration on the
assembly of the device and how it is utilized to administer the medication. Participants in
the research study were then asked to demonstrate assembly and utilization of the device.
This was observed, and the results recorded. Participants in the study were asked to return
for the second session two weeks after their initial session. During the second session,
they did not receive any of the educational materials, and were asked to demonstrate how
to use the device and observed during this process.
Sample Size. In order to achieve a Confidence Level (CL) of 95%, and a
Confidence Interval (CI) of 10%, there needed to be 96 participants, or 24 participants
per group since there are four groups. There were 94 individuals who attended the first
session, and 90 who completed both sessions. A total of 89 individuals completed the exit
survey. In order to obtain a CI of 5%, then there would have needed to be 384
participants, or 96 participants per group. Since the participants were recruited through
the Participant Pool in the Educational Psychology Program, there was estimated to be
between 100 to 300 participants, so a CI of 5% would not have been practical. With this
in mind, a maximum limit of 120 participants was included in the IRB description of the
study. While this resulted in a smaller number of participants per group, it allowed for
enough participants to determine if there are differences between the educational
modalities of the interventions being utilized. Each intervention group had between 22 to
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26 participants.
Sampling. The four-group design of the experiment allowed a simple random
assignment method to each group to be utilized. To assure random assignment and
achieve the group determination, each participant was asked to randomly draw a card
from two decks of standard playing cards, with an additional 16 cards (4 cards of each
suit) added to the pile for a total of 120 cards without jokers. This resulted in 30 cards of
each suit in the deck. Each of the four suits corresponded to one of the four different
educational modality groups: subjects who draw a card with the suit of spades were
placed in group one; subjects who draw a card with the suit of hearts were placed in
group two; subjects who draw a card with the suit of clubs were placed in group three;
and, subjects who draw a card with the suit of diamonds were placed in group four.
Group and Observation Design. There were four groups with two observations
conducted on each participant. The initial observation, and a second observation which
occurred two weeks after the initial observation appointment. Utilizing a twoappointment observation frequency with a two-week delay helped to ameliorate
repetitions of the participants needing to demonstrate the device assembly and use. It is
important to minimize the frequency the participants demonstrate the assembly and use of
the device because multiple repetitions could potentially skew the data due to increased
familiarity with the device. The two-week delay between the first and second
observations allowed for the ability to measure the possible encoding of the information
to the long-term memory and recall of the information by the participant.
Once the group assignment was made, each participant was shown into a room
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with a rescue mannequin already present. The research assistants followed a set script for
each group (Appendix G). They were told they will be given the pieces of a device used
to deliver naloxone, a medication which reverses opioid overdoses. For the first
observation:
Individuals assigned to the first group were given no other additional instructions
other than to try and assemble and demonstrate the use of the device as well as the
information printed on the box of the device.
Individuals assigned to the second group were given the written instructions,
including visual representation (Appendix D), and were given 45 seconds to read and
review the information.
Individuals assigned to the third group were shown a 45-second video of a person
demonstrating the device being assembled and used properly.
Individuals assigned to the fourth group were shown how to assemble and use the
device in a face-to-face setting. These educational sessions were conducted by the same
individual who demonstrated the device in the video, and to help maintain fidelity to the
curriculum. The timing of the demonstration was as close to 45 seconds in duration as it
was possible for the demonstrator to complete each time.
In each observation, the time measurement for the participant to demonstrate
assembly and use of the device started once the participant was asked to begin the
demonstration by the observing research assistant stating, “Start now”. For the instances
where there were educational instructions provided, the education was conducted first;
then, the participant was given the device and asked to demonstrate assembly and use.
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The time the participants had to view the instructions and education portion of the session
was not be counted in the length of time for the participant to demonstrate assembly and
usage.
Measurement Scales. The device has three parts for assembly. A medication vial
and syringe barrel (no needle affixed on the injection end) in a box, and then a separate
atomizer. Once assembled, the device is administered with half of the dosage in one
nostril, and the other half of the dosage in the other nostril. So, the measurements used
for the observations included a simple 4-point scale (0 – 1 – 2 – 3) to indicate the ability
to correctly assemble the device and a second 4-point scale to indicate correctly
administering the medication in a way which would enable the overdosing person to
receive at least half of the dosage of naloxone. For the assembly scale: Zero indicates
unsuccessful assembly; one indicates unsuccessful assembly with the atomizer attached
to the syringe barrel, but not the medication vial (with no opportunity to administer the
medication); three indicates partially successful assembly with the medication vial being
attached to the syringe barrel, but not the atomizer; and, four indicates all three pieces are
successfully assembled.
For the administration (or use) scale: zero indicates unsuccessful administration
with no naloxone being administered to the overdosing individual; one indicates partially
successful administration with the medication being expressed in only one nostril; two
indicates partially successful administration with the medication being expressed orally;
and, four indicates successful administration with the medication being expressed in both
nostrils. The device would usually contain a 2mg/2ml solution of naloxone. However, for
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study purposes, the device contained only water. The third measurement utilized was the
length of time it takes for each individual to attempt assembling and demonstrating the
use of the device, with the time marked at the point where the device is assembled, and
again at the end of the participant demonstrating administration of naloxone on the rescue
mannequin. If an individual is not breathing when they overdose, the ability to
successfully reverse an opioid overdose with naloxone reduces to minimal after
approximately 5 minutes due to the lack of oxygen to the brain (NIH, 2007). So, the
participants could continue until they successfully assembled and demonstrated the use of
the device, or indicated they are not able to complete the tasks and wish to stop. If they
took longer than 5 minutes, or indicated they wish to stop, it was designated as an
unsuccessful attempt.
Initial Observation. For the Initial Intervention appointment session, each
subject in each of the four groups was asked to assemble and demonstrate how the device
would be used on an individual experiencing an opioid overdose after they were provided
with the appropriate educational modality. A rescue mannequin was used to simulate an
individual so the participant could demonstrate the processes involved. During this
demonstration, the observer recorded the participants’ results using the two measurement
scales and the time to complete each of the two tasks. The observers did this without
prompting or giving clues by either verbal or non-verbal means as to how the participant
did in their demonstration.
Second Observation. For the second observation session, the groups consisted of
the same participants. The observations were again conducted separately with each
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participant. Each participant was in a room with a rescue mannequin. The research
assistant used the same script to start each session and provide instructions (Appendix H),
and the participants were given the pieces of the device. They were then asked to
demonstrate how the pieces of the device are assembled and used to reverse an opioid
overdose by demonstrating on the rescue mannequin. The educational information was
not provided to the participants for the second observation session. The lack of the
educational material on the assembly and usage of the device was purposeful to
determine if the exposure to the material one time allows for the encoding the
information in long-term memory.
Curriculum
The curriculum used for the educational component of this study was a portion of
the curriculum utilized and approved by the New Mexico Department of Health
(https://nmhealth.org/about/phd/idb/hrp) for overdose prevention and education
(Appendix I). Because this study focused on assembly and use of naloxone, only the
portion of the curriculum describing the assembly and use of the naloxone delivery
device was provided as part of the study. The curriculum from the New Mexico
Department of Health has been used for over a decade, and is considered a standard
curriculum nationally. While updates to this curriculum occur when devices are changed,
the device and curriculum being used in this study is one which has been utilized by the
NMDOH since 2005-2006 (NMDOH, 2017).
Measurement Tools
Prior to the initial Intervention and Observation, each participant completed the
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consent for the study (Appendix A) a short demographic survey including age, gender at
birth, current gender identity, and ethnicity (Appendix B). There was also a questionnaire
regarding prior knowledge of opioid overdoses and naloxone, as well as possible intrinsic
and extrinsic motivators (Appendix C). This included questions regarding whether they
have ever experienced an opioid overdose, if a family member or close friend has
experienced one, how many events (possible opioid overdoses) and the outcome of any
reported event. The surveys were coded, and no identifying information was collected on
the surveys. Each participant was given their code, and the methodology used to create
the code. This ensured anonymity for the participant regarding their responses to the
questions. Their code was recorded on all surveys, instruments, and questionnaires, and
included with their scores from the observations. The code was created by using the first
two letters of their first name, the first two letters of the participants’ mothers’ first name
(if the participant does not have a mother, the option to use the first two letters of their
father’s first name would have been provided, but the situation did not arise), and the last
two digits of their year of birth.
During the initial intervention, the observer recorded the time it took for the
participant to assemble the device and demonstrate it on the rescue mannequin. In
addition, the observer had a checklist to ensure they had the proper steps for assembly
and administration readily available. These steps include attaching the atomizer correctly
to the barrel, attaching the medicine vial correctly to the barrel, and demonstrating the
proper use of the medication by spraying it into the nostril. The steps for attaching the
atomizer and the medicine vial has four possibilities: unsuccessfully attached, partially
35

attached (atomizer), partially attached (medicine vial), and unattached (unsuccessful).
A correctly attached atomizer means the atomizer is attached in such a way as the
liquid is atomized through the atomizer when demonstrated and does not leak out the
sides or at the attachment location. A partially attached atomizer means the atomizer has
been attached to the syringe barrel. An unattached atomizer is one which has not been
attached at all, or where the attachment is so loose as to cause the atomizer to fall out
during the demonstration.
The second partially attached option means the medicine vial is attached to the
syringe barrel without the atomizer being attached. A correctly attached medicine vial is
one which is attached in such a way so the rubber stopper inside the vial is pierced
allowing the liquid to exit the medicine vial when demonstrated. A partially attached
medicine vial is one which is attached in such a way so some of the liquid is expressed
when demonstrated, but not all. An unattached medicine vial is one in which the interior
rubber stopper is not pierced at all, and no liquid exits the medicine vial when
demonstrated, or where the medicine vial is attached loosely to the barrel and falls out
during the demonstration.
An unattached or unassembled atomizer and medicine vial resulted in an
unsuccessful demonstration. This included when the atomizer or medicine vial was not
attached at all, or if any of the pieces of the device fell off the assembly during the
demonstration. In addition, this included instances where the participant tried to force the
medicine vial in such a way as to cause it to break.
The next item on the measurement checklist is whether the participant uses the
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device in the appropriate way. For the demonstration, it was recorded as used correctly,
partially correctly (two options), or incorrectly. For the device to be used correctly, it
must be inserted (or described as needing to be inserted) into a nostril, or placed at the
opening for a nostril, and the liquid in the device expressed, half in one nostril, and then
the other half in the second nostril. To be used partially correctly, the device would have
been inserted into the nostril (or described as being inserted into the nostril), and then
expressed fully into one nostril. The alternative for partially correctly was for the device
to be inserted into the mouth and expressed. To be used incorrectly, none of the previous
methods were demonstrated. As a note, there is a third method which could potentially
have been used or described, which is rectally, however the rescue mannequins used for
the demonstration were not equipped to handle this situation, and this is a rare possibility.
While some participants in overdose prevention education programs are taught this as a
last resort, it has not been reported to have occurred in the literature to date, other than
anecdotally and unconfirmed by participants in the NMDOH Opioid Overdose
Prevention and Naloxone Distribution program (NMDOH, 2017).
For the second observation, the same measurements were utilized. After the
observation session, the participants were asked to complete a post-observation survey
(Appendix F). This survey asked if participants had sought out educational material on
naloxone during the two-week period between the first observation session and the
second. If they did seek out additional material, what type of material – written, visual,
audio, or combined – and how much time they spent reviewing it in thirty-minute
increments. The post-observation survey also included questions on whether the
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participant thought the education on naloxone is important and why they think it is
important.
At the end of the second observation session, all participants were offered the full
training by a certified NMDOH Harm Reduction Specialist, and provided with
information as to where they could obtain naloxone for their own emergency use in order
to not restrict their access to this potentially life-saving medication. Ten of the ninety
participants elected to complete the full training. All participants were provided with the
written curriculum and information on where and how to obtain naloxone.
Minimizing Risk
In order to ensure participants do not experience unusual stressors or negative
reactions, all participants had the option to end their participation in the study at any time.
A basic description of the study was provided as a part of the consent form. In addition, if
any of the material was found to be distressing to the participant they were offered
resources for counseling. None of the participants expressed the need for referral to
counseling during the course of the study. Participants were also provided with contact
information on where to obtain counseling in the event there was a delayed negative
reaction. In addition, all participants were offered the full curriculum and training for
overdoes prevention and education at the conclusion of the second observation.
Participants were provided with contact information for locations where they can obtain
naloxone for their personal use or use on a bystander they may encounter who
experiences an overdose.
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Confidentiality
Although this study utilized a code system to ensure participants personal
information is kept anonymous, all individuals involved in conducting the research
completed HIPAA training to ensure confidentiality laws and procedures are understood
and maintained. All researchers participating in the study also completed the required
University of New Mexico courses on Human Research through the Office of the Internal
Review Board. Records of this training will be kept for a minimum of three years. Any
breach in confidentiality will be reported immediately to the principle investigator (PI)
and the PI will report it to the appropriate University authorities as soon as possible.
Data Protection
All data gathered during this research will be maintained securely. To ensure a
level of security so there is minimal possibility for a security breech, the data will be kept
on an encoded electronic media storage device at all times. Any names or identifying
information will be kept only until the conclusion of the research project, and then
destroyed in order to maintain privacy for participants. The exception to this is the
Consent Form, which will be kept under a double lock for three years, and then destroyed
in accordance to DOD destruction of private material procedures.
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CHAPTER 3: RESULTS
Demographics
The demographic information of the participants has been summarized for the
following categories: gender identity [Table 3.0], ethnicity [Table 3.1], age [Table 3.2],
and a graph for year of birth (figure 3.1). There was a total of 94 individuals participating
in at least one observation session, and 90 completing both observation sessions. Out of
the 90 participants who completed both observation sessions, only one did not complete
all surveys, and the one survey they elected to not complete was the final, postexperiment exit survey. The participants indicated a current gender identity of 24.47%
male, 73.40% female with one person indicating they were transgender (unspecified) and
1 person declining to answer the question [Table 3.0]. The survey did include options for
Transgender Male to Female and Transgender Female to Male, but no participants
selected either of these options.
Table 3.0
Gender Identity

Male
Female
TransgenderUnspecified
Decline to
Answer
Total:

Gender at Birth Current Gender
%
%
Identity
Gender at Birth Current Gender
Identity
24
23
25.53%
24.47%
70
69
74.47%
73.40%
0
1
0.00%
1.06%
0

1

0.00%

1.06%

94

94

100.00%

100.00%

For ethnicity, a two-part question was asked. Part one of the question asked if the
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participants were of Hispanic descent. 56.38% of the participants indicated they were of
Hispanic descent, and 43.61% indicated they were not of Hispanic descent. Part two of
the ethnicity question asked about other ethnic background indicators, including
Hispanic. Participants were allowed to select as many different ethnic options, and so the
following table adds up to more than 100%. Only 16 (17.02%) of the participants selected
more than one option, and one of these (1.02%) selected three options. Indicating a
17.02% of the participants identified as multi-ethnic. Table 3.1 also shows the majority of
participants selected Hispanic (51.06%), with the next largest category being Caucasian
at 46.80% for the second part of the ethnicity question.
Table 3.1
Frequency for Participant Ethnicity
Ethnicity:
African-American
American Indian-Alaskan
Native
Asian-Pacific Islander
Caucasian
Hispanic-Latino
Unknown
Other*
Decline
Total:

N

%
3

3.19%

8
5
44
48
0
2
1
111

8.51%
5.32%
46.81%
51.06%
0.00%
2.13%
1.06%
118.09%

The Gender Identity information gathered shows the ratio of participant gender
identity does not match the general population in New Mexico, and has a skew toward
female participants, whereas according to the US Census conducted in 2010, the general
population is 50.5% female in New Mexico (US Census, 2016). The ethnicities reported
are closer to the rates of the general population with 48.5% Hispanic and 38.1%
41

Caucasian in New Mexico according to the US Census in 2016; and, there were 51.6%
participants identifying as Hispanic and 46.8% participants identifying as Caucasian in
the study; this is a variation of 3.1% and 7.3% respectively. The next highest ethnicity
reported is Native American/Alaskan Native at 8.51% in the study as compared to 10.6%
in New Mexico general population (US Census Bureau, 2016).
Age of the participants ranged from 18 to 57, with 72 of the participants being 25
years old or younger. There were only 5 individuals who were over the age of 40. The full
graph for year of birth can be seen in Figure 3.1 and the frequency of age groups in Table
3.2. Among those who overdose in New Mexico, 8.56% are 24 or younger, 86.69% are
between the ages of 25-64, and 4.75% are 65 or older (NMDOH, 2017, p. 31).

Figure 3.1 Frequency Graph for Participant Year of Birth
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Table 3.2
Frequency for Participant Age
Age
N
<20
28
21-25
44
26-30
5
31-35
6
36-40
6
40+
5

%
29.79%
46.81%
5.32%
6.38%
6.38%
5.32%

Prior Knowledge Survey
The Prior Knowledge Survey instrument responses were also compiled. This
survey helped to provide a snapshot of the cross-section knowledge base of the
participants. It also helps to determine possible biases toward specific populations due to
their levels of prior knowledge. Items not recorded properly due to either the participant
having left the question blank have been excluded rather than trying to use average or
means substitution processes since this is a small sampling, and only a few items were
unreported. This allows for utilization of the data recorded rather than approximations.
The Prior Knowledge Survey included questions about overdose experiences both
for the participant themselves and for family or close friends. None of the participants
reported having experienced an opioid overdose themselves. Thirteen (13.82%) of the
participants reported having had a family member or close friend having experienced an
opioid overdose, and six (46.15%) of these participants stated there had been three or
more opioid overdose situations. This equates to 6.38% of the overall study participants
had reported three or more opioid overdose experiences by family or close friends. From
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the total number of overdoses, fifteen incidences had reported outcomes. Ten reported the
individual who experienced the overdose survived. Five reported the individual who
experienced the overdose was deceased after the incident. This is a 33% mortality ratio
for the incidents where the outcome was known by the participant.
The Prior Knowledge Survey included questions about general information
regarding naloxone [Table 3.3]. The first question asked if the participant had heard of
naloxone, and the second asked if they knew naloxone could reverse an opioid overdose.
The third question asked if they were interested in learning how to use naloxone. While
81 participants stated they would like to learn more about how to use naloxone, only 29
had heard of naloxone previously, and 23 reported they knew it could reverse an opioid
overdose [Table 3.3].
Table 3.3
Questions about Naloxone

Have you heard of naloxone?
If “yes” (to the previous
question), did you know naloxone can
reverse an opiate overdose?
Are you interested in learning
how to use naloxone?

Yes

No

Decline to
answer

29

64

1

23

6

0

81

8

5

Observation Sessions
After the Prior Knowledge Surveys were completed, participants selected a card
from the deck of playing cards to determine the type of educational session they would
receive. The frequency of the number of participants in each group are reported in table
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form with the suit selections of the participants, and are listed in the following table
[Table 3.4]. This shows the variation of suit selection has a range of 22 to 26 members or
23.4% to 27.7% in each group.
Table 3.4
Selection Frequency and Percentages
N
No education
Written education

23
26

%
24.5%
27.7%

Video education

23

24.5%

In-person education

22

23.4%

Total

94

100.0%

The frequency for completion of assembly [Table 3.5] and administration [Table
3.6] is reported here to show the small number of individuals who were not able to
complete the assembly or administration. While there is a difference between the groups
as to which modality of education resulted in more complete assembly and
administration, overall, it was less than 26% percent of the total number of participants
who could not correctly assemble and administer the medication. Two-point-two percent
(2.2%) of the participants were not able to administer the medication at all. Twenty-threepoint-four percent (23.4%) of the participants could demonstrate administering the
medication in a way which could have been at least partially effective, either by
administering in one nostril or orally. The remaining 74.4% of the participants were able
to administer the medication in the prescribed manner with medication expressed in both
nostrils. [Table 3.6].
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The frequency table [Table 3.5] for the assembly of the device during the first and
second observations shows the frequency of participants, the percent, and the percent
with missing observations excluded based on their ability to successfully assemble the
device.
Table 3.5
Frequency Table for Assembly Demonstrations
Observation 1
%

N
Unsuccessful
Atomizer
attached
Medication
Vial
attached
Fully
assembled
Total
Missing
Final Total

%
missing
observations
excluded

Observation 2

N

%

%
missing
observations
excluded

5

5.30%

5.30%

0

0.00%

0.00%

2

2.10%

2.10%

8

8.50%

8.90%

5

5.30%

5.30%

5

5.30%

5.60%

82

87.20%

87.20%

77

81.90%

85.60%

94

100.00%

100.00%

90
4

95.70%
4.30%
100.00%

100.00%

The frequency table [Table 3.6] for the administration of the medication during
the first and second observation shows the frequency of participants, the percent, and the
percent with missing observations excluded based on their ability to successfully
administer the device.
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Table 3.6
Frequency Table for Administration Demonstrations
Observation 1
%
missing
N
%
observations
excluded
Unsuccessful
10
10.60%
10.60%
Partial – One
8
8.50%
8.50%
nostril

Observation 2

2

2.10%

%
missing
observations
excluded
2.20%

14

14.90%

15.60%

N

%

Partial - Oral

15

16.00%

16.00%

7

7.40%

7.80%

Successful

61

64.90%

64.90%

67

71.30%

74.40%

Total
Missing

94

100.00%

100.00%

90
4

95.70%
4.30%

100.00%

94

100.00%

Total

The frequency table showing the number of successful assembly and
administration attempts and the ratio of successful assembly and administration when
compared to the initial group assignment is in Table 3.7. It shows 90.91% of the
participants who received the in-person education were able to successfully assemble and
administer the naloxone two weeks after the educational session. The video education
group has a ratio of 78.26%, with the written education group having a ratio of 50.00%,
and the no education group with a 34.78% ratio.
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Table 3.7
Frequency Table with Both Successful Assembly and Administration Attempts
Initial
Group
Assignment
N

Observation 1

23

1

%
1.06%

26

15

Video
demonstration

23

In-person
demonstration

No education
Written
education

Total
Missing
Total

N

Observation 2

N
8

%
8.89%

15.96%

13

14.44%

22

23.40%

18

20.00%

22

22

23.40%

20

22.22%

94

60
34

63.83%
36.17%

59
31

65.56%
34.44%

94 100.00%

90

100.00%

Ratio of
Successful
Assembly and
Administration
to Initial Group
Assignment
34.78%
50.00%
78.26%
90.91%
62.77%

The frequency tables including all assembly and administration times for all
participants can be found in Appendix J. These tables show all times for the observations
for both partially completed and for incomplete attempts of the demonstration. These
frequency tables allow for cross analysis regarding time frame for the completion or
cessation of the attempt to complete the demonstration.
For the first observation, fewer individuals were able to successfully complete
the device assembly and administration than during the second observation. From the noeducation group only 78.26% of the participants were able to fully assemble the device,
and only 4.35% were able to fully administer it during the first observation. This
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increased to 82.61% for assembly and 43.48% for administration during the second
observation. During the first observation, the group with the written instructions were
able to correctly assemble the device 76.92% of the time, and correctly administer
61.54% of the time. During the second observation, the ratio of these participants to
correctly assembly decreased to 75.00% and those able to correctly administer increased
to 66.67% [Table 3.8].
However, the two groups who were provided with either the video or the inperson demonstration were able to demonstrate the assembly and administration of the
device in the first observation, with only one individual not being able to do so fully from
the video group with a total ratio of 95.65% of the assembly and administration attempts
being successful, and 100% success for those within the in-person group for both
assembly and administration. In the second observation, these two groups had similar
results, with two individuals not being able to fully assembly the device from the video
group for a total of 90.84% and one from the in-person demonstration group for a total of
95.45% successful. For the administration portion, only two individuals from the video
group and one from the in-person demonstration group could not fully administer the
naloxone with total success rates of 95.25% (video) and 95.45% (in-person) respectively
[Table 3.7].
In Table 3.9, the percentage change for each category within each group can be
seen, adjusted for the loss of 4 participants – two from the written education group and
two from the video education group. While there is an increase in the ratio of individuals
from the no-education group to assemble the device (4.35%), this is primarily from an
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increase in individuals attaching the atomizer of the device (8.70%) but, with a reduction
in the participants who attach the medication vial (-4.35%). So, while this appears to be
more successful, in practice, it leaves the individual without the ability to administer the
naloxone since the medication vial is not attached. The same situation occurs in the group
which received the written instructions, which saw a decrease in the number of
participants who were able to fully assemble the device.
For the administration, while there was a decrease in the number of individuals
who were able to fully assemble and administer the naloxone, this was less than 5%
overall, and may be accounted for by the lack of encoding into long-term memory by
those individuals. In both the video and in-person demonstration groups, only one person
was not able to assemble the device and fully administer the naloxone.
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Table 3.8
Frequency Tables for Observation Counts both Assembly and Administration
Count: Observation 1 - Assembly
None Atomizer
Vial
Full
Total
No education
2
0
3
18
23
Written education
2
2
2
20
26
Video education
1
0
0
22
23
In-person education
0
0
0
22
22
Totals:
5
2
5
82
94
Count: Observation 1 - Administer
OneNone
nostril
Oral
Full
No education
5
4
13
1
Written education
4
4
2
16
Video education
1
0
0
22
In-person education
0
0
0
22
Totals:
10
8
15
61

Total
23
26
23
22
94

Ratio: Observation 1 - Assembly
None Atomizer
Vial
Full
No education
8.70%
0.00% 13.04% 78.26%
Written education
7.69%
7.69% 7.69% 76.92%
Video education
4.35%
0.00% 0.00% 95.65%
In-person education
0.00%
0.00% 0.00% 100.00%

Total
100.00%
100.00%
100.00%
100.00%

Ratio: Observation 1 - Administer
OneNone
nostril
Oral
Full
No education
21.74%
17.39% 56.52%
4.35%
Written education
15.38%
15.38% 7.69% 61.54%
Video education
4.35%
0.00% 0.00% 95.65%
In-person education
0.00%
0.00% 0.00% 100.00%

Total
100.00%
100.00%
100.00%
100.00%
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Count: Observation 2 - Assembly
None Atomizer
Vial
Full
No education
0
2
2
19
Written education
0
4
2
18
Video education
0
1
1
19
In-person education
0
1
0
21
Totals:
0
8
5
77

Total
23
24
21
22
90

Count: Observation 2 - Administer
OneNone
nostril
Oral
Full
No education
1
6
6
10
Written education
1
6
1
16
Video education
0
1
0
20
In-person education
0
1
0
21
Totals:
2
14
7
67

Total
23
24
21
22
90

Ratio: Observation 2 - Assembly
None Atomizer
Vial
No education
0.00%
8.70% 8.70%
Written education
0.00%
16.67% 8.33%
Video education
0.00%
4.76% 4.76%
In-person education 0.00%
4.55% 0.00%

Full
82.61%
75.00%
90.48%
95.45%

Total
100.00%
100.00%
100.00%
100.00%

Ratio: Observation 2 - Administer
OneNone
nostril
Oral
Full
No education
4.35%
26.09% 26.09% 43.48%
Written education
4.17%
25.00% 4.17% 66.67%
Video education
0.00%
4.76% 0.00% 95.24%
In-person education 0.00%
4.55% 0.00% 95.45%

Total
100.00%
100.00%
100.00%
100.00%
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Table 3.9
Frequency Tables for Count Differences Between Observation 1 and Observation 2
Count Difference in O2 vs O1 - Assembly
None
Atomizer
Vial
Full
Total
No education
-2
2
-1
1
0
Written education
-2
2
0
-2
-2
Video education
-1
1
1
-3
-2
In-person education
0
1
0
-1
0
Totals:
-5
6
0
-5
-4
Count Difference in O2 vs O1 - Administer
OneNone
nostril
Oral
Full
No education
-4
2
-7
9
Written education
-3
2
-1
0
Video education
-1
1
0
-2
In-person education
0
1
0
-1
Totals:
-8
6
-8
6

Total
0
-2
-2
0
-4

Ratio Difference in O2 vs O1 - Assembly
None
Atomizer
Vial
Full
No education
-8.70%
8.70% -4.35% 4.35%
Written education
-7.69%
8.97% 0.64% -1.92%
Video education
-4.35%
4.76% 4.76% -5.18%
In-person education
0.00%
4.55% 0.00% -4.55%

Total
0.00%
0.00%
0.00%
0.00%

Ratio Difference in O2 vs O1 - Administer
OneNone
nostril
Oral
Full
No education
-17.39%
8.70% 30.43% 39.13%
Written education
-11.22%
9.62% -3.53% 5.13%
Video education
-4.35%
4.76% 0.00% -0.41%
In-person education
0.00%
4.55% 0.00% -4.55%
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Total
0.00%
0.00%
0.00%
0.00%

Analysis
The observation data from the checklist were entered into SPSS. One-way
Analysis of Variance (ANOVA), was used to examine whether the participant times to
complete both assembly of the device and administration of the medication is a function
of the modality of education each participant received. An alpha level of .05 was used for
all included analyses. The Levene statistical analysis was used to test homogeneity of
variance. The independent variable is the group membership representing four different
educational methods: 1) no additional education; 2) written educational material; 3) video
educational demonstration; and 4) an in-person demonstration. The dependent variables
are time of assembly and time to administration. In table 3.9, each of the observation
points is reported separately for: 1) observation 1 – time to assemble the device; 2)
observation 1 – time to administer the medication; 3) observation 2 – time to assemble
the device; and 4) observation 2 – time to administer the device. The null hypothesis
states each group mean is equal and the alternative hypothesis states there are significant
differences for at least two of the group means. The p value for both measured items in
the first observation is significant, with assembly time F(3, 89) = 7.445, p = .000, and
administer time F(3, 90) = 11.196, p = .000 [Table 3.10]; this includes the time it takes
participants to assemble the device and the time it takes for participants to administer the
medication. This signifies the rejection of the null hypothesis for the first observation,
with the p value being less than the alpha level of .05. During the second observation, the
time for assembly was not significant F(3, 86) = 1.641, p = .186; and the time for
administration was also not significant F(3, 86) = 2.449, p = .069 [Table 3.10] with the p
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values being greater than the alpha level of .05. This signifies the retention of the null
hypothesis for both measured items in the second observation, including the assembly
and administration times. See table 3.10 for the means and standard deviations for each of
the groups.
Table 3.10
Analysis of Variance for Assembly and Administration Times
Sum of
Mean
Squares
df
Square
Observation 1 Between 66107.035
3 22035.678
Assembly
Groups
Time
Within
263416.772
89 2959.739
Groups
Total
329523.806
92
Observation 1 Between 100160.728
3 33386.909
Administration Groups
Time
Within
269045.102
90 2989.390
Groups
Total
369205.830
93
Observation 2 Between
4169.324
3 1389.775
Assembly
Groups
Time
Within
72852.732
86
847.125
Groups
Total
77022.056
89
Observation 2 Between
7103.006
3 2367.669
Administration Groups
Time
Within
83127.094
86
966.594
Groups
Total
90230.100
89

F
7.445

Sig.
0.000

11.168

0.000

1.641

0.186

2.449

0.069

Looking at the descriptive analysis for the groups, including time measured for
both assembly and administration, there are differences which can clearly be seen when
utilizing the means for each group [Table 3.11]. For example, the mean for the no
education group for time of assembly is 101.3 seconds (1 minute 41.3 seconds), while the
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mean assembly time for the group with the in-person demonstration is 61.74 seconds.
This difference in 39.56 seconds is of significance in reaction time. This difference
parallels for the same groups in the Administration time, with 129.86 seconds and 82.04
seconds respectively, for a difference of 46.18 seconds.
The times during the second observation are closer, with the no-education group
having a mean of 64.37 seconds to administer, and the in-person educational group
having a mean of 48.63 seconds [Table 3.11]. However, more of the individuals in the
no-education group were not able to assemble the device, so this reduces the number of
individuals who could have successfully administered the medication with 43.48% of the
participants who received no education when compared to 95.45% of the participants in
the in-person education group [Table 3.12]. One of the interesting items is the mean
administration time for the video group is 44.71 seconds, which is 3.92 seconds less than
the in-person demonstration group [Table 3.11].
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Table 3.11
Observation 1 and Observation 2: Assembly and Administration Descriptive Information

N
Mean
Observation 1 Assembly Time

Std.
Deviation

Std.
Error

95% Confidence
Interval for Mean
Lower
Upper
Bound
Bound

Min

Max

No Education

23

101.3043

79.14167

16.50218

67.0809

135.5278

0.00

346.00

Written
Education
Video
Education
In-person
Education
Total

26

69.3077

68.07688

13.35097

41.8108

96.8045

0.00

298.00

22

40.8182

17.19534

3.66606

33.1942

48.4422

21.00

89.00

22

32.3636

13.00383

2.77243

26.5981

38.1292

19.00

76.00

93

61.7419

59.84798

6.20595

49.4164

74.0675

0.00

346.00

Observation 1 Administration Time
No Education

23

129.8696

79.06689

16.48659

95.6785

164.0607

39.00

346.00

Written
Education
Video
Education
In-person
Education
Total

26

93.3077

69.65272

13.66002

65.1743

121.4410

27.00

298.00

23

56.0000

16.41784

3.42336

48.9004

63.0996

32.00

100.00

22

45.9545

14.29778

3.04830

39.6153

52.2938

28.00

93.00

94

82.0426

63.00758

6.49874

69.1374

94.9478

27.00

346.00

Observation 2 Assembly Time
No Education

23

51.3478

42.09363

8.77713

33.1452

69.5505

17.00

175.00

Written
Education
Video
Education
In-person
Education
Total

24

46.2917

29.75330

6.07337

33.7279

58.8554

18.00

133.00

21

33.5238

10.62365

2.31827

28.6880

38.3596

18.00

66.00

22

38.5909

23.14892

4.93537

28.3273

48.8546

17.00

121.00

90

42.7222

29.41796

3.10093

36.5607

48.8837

17.00

175.00

Observation 2 Administration Time
No Education

23

64.3478

42.86300

8.93755

45.8125

82.8832

23.00

192.00

Written
Education
Video
Education
In-person
Education
Total

24

64.2500

34.35651

7.01299

49.7425

78.7575

26.00

152.00

21

44.7143

12.71669

2.77501

38.9257

50.5029

26.00

83.00

22

48.6364

24.22621

5.16504

37.8951

59.3777

24.00

138.00

90

55.9000

31.84056

3.35629

49.2311

62.5689

23.00

192.00
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An additional ANOVA was conducted with group membership representing the
four different educational methods as the independent variable, and the total time to
assemble and administer the device during Observation 1 and again for Observation 2 for
the dependent variable; only those attempts which had completed successful assembly
and administration in each observation session. Since this analysis excluded unsuccessful
attempts at assembly, this was not analyzed separately as it was in the previous ANOVA.
These results can be seen in Table 3.12. It includes the p value for the Observation 1 to
have significance F(3, 56) = 5.781, p = .002; and Observation 2 to not have significance
F(3, 55) = 2.031, p = .120.
Table 3.12
Analysis of Variance – Both Successful Assembly and Administration Attempts
Sum of
Mean
Squares
df
Square
F
Sig.
Between
24257.095
3
8085.698 5.781
0.002
Observation 1 Groups
Within
78323.888 56
1398.641
Groups
Total
102580.983 59
Between
3286.777
3
1095.592 2.031
0.120
Observation 2 Groups
Within
29668.952 55
539.435
Groups
Total
32955.729 58

When the unsuccessful attempts for both assembly and administration are
excluded from this comparison, the written education group had 13 individuals who were
successful with a mean time of 54.7500 seconds and the no education group had 8
individuals with a mean time of 61.2308 seconds. The mean time to administer the device
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remain similar for both the video education group and the in-person education group. The
18 participants who were able to completely assemble and use the device in the video
group had a mean time of 43.0556 seconds. There were 20 participants in the in-person
education group who completed both assembly and use of the device and had a mean
time of 44.3000 seconds [Table 3.13].
Table 3.13
Time to Administer: Unsuccessful Assembly and Administration Excluded
95% Confidence
Interval for Mean
N
Observation 1

Mean

Std.
Deviation

Std.
Error

Lower
Bound

Upper
Bound

Minimum

Maximum

39.00

39.00

No
Education

1

39.0000

Written
Education

15

95.9333

69.74491

18.00806

57.3099

134.5568

27.00

262.00

Video
Education

22

56.0000

16.80419

3.58267

48.5494

63.4506

32.00

100.00

In-person
Education

22

45.9545

14.29778

3.04830

39.6153

52.2938

28.00

93.00

Total

60

62.0167

41.69725

5.38309

51.2451

72.7882

27.00

262.00

8

54.7500

33.31988

11.78036

26.8939

82.6061

23.00

104.00

13

61.2308

36.83557

10.21635

38.9713

83.4903

26.00

152.00

Video
Education

18

43.0556

9.87851

2.32839

38.1431

47.9680

26.00

68.00

In-person
Education

20

44.3000

14.42987

3.22662

37.5466

51.0534

24.00

79.00

Total

59

49.0678

23.83699

3.10331

42.8558

55.2798

23.00

152.00

Observation 2
No
Education
Written
Education

Using the Levene statistical analysis to test for homogeneity of variance, the four
different observation points result in the following: 1) observation 1 – time for assembly
[Levene F(3, 89) = 10.665 p<.000]; 2) observation 1 – time for administration [Levene
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F(3, 89) = 8.940 p<.000]; 3) observation2 – time for assembly [Levene F(3, 90) = 4.152
p<.000]; and 4) observation 2 – time for administration [Levene F(3, 86) = 5.919 p<.001].
When utilizing the means, it shows significant difference for homogeneity of variance
with a p value less than .05 for all tests. Thus, the assumption of homogeneity of variance
is not met. However, since the sample size for each group is similar, the Type I error
effect is minimal, so the ANOVA can still be used.
Since the measure for administration is the final step to successfully use the
naloxone delivery device, a Pearson’s Chi Square test was run for this set of data. For
this, the two variables examined are the ability to administer the device properly and the
educational modality received during the intervention. The null hypothesis is the ability
to administer the device properly is independent of the educational modality received and
the alternative hypothesis is the ability to administer the device properly is not
independent of the educational modality received. The relationship between these
variables was significant, X2 (9, N=90) = 27.477, p = .001 showing there is a significant
difference between the different groups and the ability to administer naloxone, the null
hypothesis is rejected, and the alternative hypothesis is accepted. This is clearly
illustrated in the graph (Figure 3.2) showing the raw data reporting the number of
participants who could fully administer the naloxone with the participants who received
either the video or in-person education better able to administer the naloxone.
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Figure 3.2 Observation 2 - Ability to Administer the Device Correctly

Post-Observation Exit Survey
The participants were also asked to complete a Post-Observation – Exit Survey
(Appendix F). In the survey they were asked if they had sought additional information
regarding naloxone between the first and second observations. Seventeen participants did
seek out additional information. Two participants from the no-instruction group sought
additional information, and five participants in each of the other three groups [Table
3.14]. All but four of the participants who sought additional information spent 30 minutes
or less with additional material, and only one participant spent between 1-2 hours
viewing additional material. Since the participants who sought additional information is
evenly spread among the groups, except the no-education group, pursuing this possible
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variance was discontinued. In addition, the participants were asked if they thought this
education was valuable, and open-ended questions regarding those thoughts (Appendix
K). Only two of the 89 participants who completed the exit survey did not think the
education was valuable, and four declined to answer or left the question blank. The two
the participants who recorded the education was not valuable went on to state: “I believe
it needs maybe more simple words to follow the directions. I believe that in a moment
when you know is life or death. You should not have to stop and read, read again to
understand simple directions.”; and, “I do not imbibe myself or affiliate with others who
do drugs.” These two responses do not indicate the information is not important, but
show the information was believed to be to complex for one participant, and not believed
necessary in the personal life of the other participant. The remaining responses were
predominantly positive, indicating an expressed belief by the participants of the
importance of education for opioid overdose prevention, response, and learning to use
naloxone (Appendices K, L, and M).
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Table 3.14
Additional Information and Type Reviewed Between Observation 1 and Observation 2
Total time spent
reviewing additional
information
Additional
Reviewed
Reviewed
Information
Written
Video
30
1
Sought
Information Information minutes hour 2 hours
NoEducation
2
1
2
2
0
0
Written
Education
5
1
4
2
2
1
Video
Education
5
1
5
4
1
0
In-person
Education
5
2
3
5
0
0

63

CHAPTER 4: DISCUSSION
Curriculum
The curriculum used for this study is the curriculum utilized by the New Mexico
Department of Health (NMDOH, 2017). This has been used for over a decade with minor
variations for this device. However, this study focused only on a small portion of the
curriculum: how to assemble and administer a nasal naloxone delivery device. The full
curriculum is a 15 to 20-minute curriculum, which includes information regarding opioid
overdose prevention, making a plan to prevent an opioid overdose, recognizing what an
opioid overdose is and the symptoms, responding to an opioid overdose with rescue
breathing and naloxone administration, and myths about opioid overdose and opioid
overdose response (see Appendix I).
This curriculum has proven successful over the years it has been in use since
participants in the NMDOH program have reported 30% or more reversals (when
compared with the number of people trained each year) in 2014 and 2015 (NMDOH,
2017). This program has individuals who inject substances and those bystanders who
associate with them regularly as their target populations for education and distribution of
naloxone. As the access to naloxone increases (NMDOH, 2017) to more individuals who
do not have behavioral risk factors as high as the core target populations of this program,
this ratio is expected to decrease. The decrease is simply due to having naloxone more
broadly available to individuals who may not have a need to use it, but have it as a
precautionary device.
The study focused on the four different modalities for education. No additional
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education, written instructions, video demonstration and in-person demonstration. It was
further focused on the assembly and administration of naloxone, rather than on the entire
curriculum in order to reduce the potential confounding factor of cognitive overload. The
results showing a marked increase in ability to assemble and utilize the device within a
short time frame from this directed educational piece is important since it shows having
an actual demonstration is important for the participant to encode the information. This
can be seen by the mean times to administer naloxone in both the video and in-person
groups [Table 3.11] with the no-education and written instruction groups taking twice as
long to administer naloxone as the group with video and in-person demonstrations during
the first observation. The no-education and written instruction groups continued to have
longer administration times when they could fully assemble the device during the second
observation.
However, times for all groups reduced from the first observation to the second
[Table 3.11], indicating there was some improvement in the assembly and administration
of the medication. Why this improvement occurred could have several possibilities,
including more familiarity with the device after having attempted to assemble and utilize
it previously. However, the idea of individuals having researched the device is diminished
in this particular study due to the post-survey responses of participants regarding their
research into the use of the device between the first and second observation [Table 3.14].
There were 17 individuals who did obtain further information, and it was evenly spread
across three of the four groups (5 members of each group), with two members of the noeducation group. When considering the changes among the three groups with the even
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distribution of additional information sought, the success rates remain within the same
ranges for success in utilizing the device.
The two groups with the most success, the video and the in-person groups both
show the participants within the groups were able to successfully assemble and
administer the device, with all but one person in the video group and two in the in-person
group who were successful at both assembly and administration were able to do so in less
than a minute total (Appendix J). It should be noted, in both the no-education and the
written instruction groups, the majority of individuals in both groups were not able to
assemble and administer the naloxone [Table 3.8]. In the second observation, four were
unable to correctly assemble the device in the no-education group, and six were not able
to do so correctly in the written material group [Table 3.8]. Also, in the second
observation, thirteen (no-education) and eight (written material) were unable to
administer the medication correctly [Table 3.8]. This is in comparison to the video group
with two individuals not assembling the device fully, and one not administering correctly;
and, the in-person group with one not assembling the device correctly, and one not
administering correctly [Table 3.8].
In conjunction with this, the times are significantly different with both the noeducation and written material group taking an average of more than a minute for those
who were able to correct administer the medication. Whereas the video and in-person
groups were able to complete the tasks in less than a minute (Appendix J). The
differences between the video and in-person groups are more difficult to parse because
while the participants who received the video information were not able to assemble the
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device and demonstrate delivery as adroitly as those in the in-person group with more
individuals assembling the device correctly during the first observation [Table 3.8].
However, during the second observation, while all participants in these two groups were
able to fully assemble the device, there were two individuals who did not fully administer
the device in the video group, and one individual who did not do so in the in-person
group [Table 3.8]. This makes it appear as though the in-person demonstration might be
slightly better for encoding of the knowledge, but with such a small sample, it is not
significant enough of a difference to make a determination. Added to this, the time for
individuals in the two groups to administer the medication is slightly faster for the video
group with a time of 44.71 seconds and 48.63 seconds for the in-person group [Table
3.8]. This alone would indicate the individuals in the video group were faster at
assembling and administering; but, when balanced with the increased failure rate, the
question becomes whether it is better to have more people administer correctly at a
slightly slower rate, but still within an acceptable time-frame, or, to have individuals
administer faster, but with a higher failure rate.
The faster administration times for the video and in-person demonstrations are
supported further when the individuals who were not able to correctly assemble or
administer the medication are excluded from the analysis. The ranking of the times
remains with the video group having the fastest time (43.05 seconds) and the in-person
group having the second fastest time (44.30 seconds) [Table 3.13]. However, more
individuals were able to complete the administration with the in-person demonstration
(20) rather than those in the video demonstration (18) [Table 3.8]. The sample size is not
67

large enough to determine if this is significant.
This scenario is a situation where administering the medication may mean the
difference between a successful opioid overdose reversal, and the person potentially
dying. A higher successful administration rate is more important than a faster time. So
long as the time to correctly administer the medication is within the acceptable range to
prevent cell death within the cerebral tissues (NIH, 2007). Both the video and the inperson demonstration group were less than a minute. The other two groups had higher
failure rates for participants to administer the medication, and so did not have the success
rate, even though for those who did correctly administer the medication did so within the
acceptable range to prevent or minimize cerebral cell death of less than 4-5 minutes
(NIH, 2007).
Study Limitations
This study focused on one device containing naloxone used in emergency opioid
overdose situations. There are other devices with varying degrees of complication, and so
may have different educational requirements. A future direction of research would be to
analyze and compare the educational requirements for different methods of utilizing
naloxone delivery
This study may also be limited by selection bias, since all study participants were
students from the University of New Mexico taking courses within the College of
Education, these results may not be able to be generalized to the public. There was also a
gender bias, with proportionally more female identifying individuals participating than
other genders [Table 3.0], and at a higher rate than found in the general population (US
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Census, 2016). There may also be an age bias, because most participants (>75%) were
under the age of 25 [Table 3.2] This could have introduced several factors, including
differences in life experiences which might influence the desire for individuals to learn
the material presented.
There is also the possibility of interaction bias, since there is an in-person
component of one of the groups, but not in others. It is possible the individuals presenting
the educational material may present it differently to different participants. In order to
reduce this possible bias, all of the individuals presenting the educational component
were trained directly by the primary researcher, utilized pre-written scripts for each
interaction, and followed the provided curriculum.
By implementing different methods to ensure the curriculum is evidence based,
such as using checklists (Abbot, 1998), helped to provide the evidence to support the
effectiveness of the curriculum and minimize the observers introducing random events. In
addition, by utilizing multiple measurements in this study, it helps to minimize other
potential confounding aspects and recognizes the need to measure each aspect of the
curriculum (Abbot, 1998). This study focused on measuring one such aspect, specifically
the device assembly and ability to utilize the device to administer naloxone.
Since the experiment was conducted in a controlled environment without a person
in an actual opioid overdose situation, it was not possible to measure the effect panic and
stress may have had on the participants as they tried to assemble and administer the
device. During stressful situations, the need to assemble a device may be cause for error
or frustration. While this aspect was not included in the study, it is an important aspect to
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consider for future research. This may also be studied through interviews with individuals
who have responded to opioid overdose situations and gathering qualitative information
from them regarding how easy or difficult they felt using the device might have been, and
what they felt their stress level was at the time of the incident.
There also may be an element of familiarity with the device created by the
participants demonstrating the assembly and administration during the first session. This
may result in some increased ability during the second session. To determine if this is
potential contributing variable, conducting research with the same educational modalities
without the initial demonstration could be beneficial.
Conclusion
This study was constructed to explore the type of educational intervention when
teaching a person how to correctly use this device and administer naloxone (medication)
to reverse potential opioid overdoses. As devices with naloxone become more readily
available, the questions regarding how much education is required remains unanswered
and largely unexplored (Coleman, 2015). This study is intended to be a starting point, to
help better guide future curricula development and implementation. Understanding the
type and level of education required to enable an individual to successfully use naloxone
will help to determine length of time and amount of resources required to be dedicated to
the implementation of programs directed to provide education and naloxone to those who
are potentially at risk for opioid overdoses, and those who might be able to respond in the
event of an opioid overdose. This is important since as naloxone becomes more widely
known and used, the fiscal impact of training becomes more important. The costs
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associated with not just the medication itself, but the time to train and the resources to
provide educational materials increases.
Additional research on opioid overdose prevention programs is needed. The
evaluative studies which have been conducted so far are based on low numbers of
participants. To be able to provide better evidence towards the efficacy of the programs,
larger samples are needed, and more studies with multiple observation points on the same
individuals in a longitudinal fashion. New Mexico is in the forefront of programs and
innovations. It continues to be a repository of resources for other places trying to start
programs, and which makes it an ideal location to conduct these research studies. Even
though overdose rates have increased in the US (Rudd, 2016), what would these rates be
without the current programs, and would the rates have increased in a higher exponential
fashion.
One primary question remaining is if the current curriculum utilized is sufficient
to teach the necessary skills for an individual to use naloxone properly. Does the 15-20minute training allow for encoding of the information in long-term memory and for the
individual to recall the information in the stressful situation of an opioid overdose. The
importance of using evidence based curriculum is paramount. Having a curriculum which
has been studied with the effects of the curriculum researched, and not just having a
curriculum implemented and observing some process outcomes, is part of what is needed
to ensure an effective educational intervention is being promulgated and provided. (Holtz,
2007).
In addition, there are educational programs to increase information and education
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among the general population which have been launched nationwide, such as the
“Prescribe to Prevent” campaign, http://prescribetoprevent.org/ (2015). This program and
others like it provide information to licensed clinicians who may prescribe opioids as
well as to any individual who seeks information on opioid overdoses and possible tools to
prevent or respond to them. Federal agencies have also provided more resources to
providers and organizations which have opioid overdose prevention or reduction as part
of their mission or activities. One such resource is the Substance Abuse and Mental
Health Services Administration (SAMHSA, 2016) made available through the website:
http://store.samhsa.gov/product/Opioid-Overdose-Prevention-Toolkit-Updated2016/SMA16-4742.
The increase in access to naloxone needs to be paired with education in order to
achieve reduction in opioid overdose mortality rates. To do so, effective educational
curricula need to be evaluated and implemented on a wide scale. By doing so, the effect
of the educational component can be increased and shown to be cost-effective both
monetarily and in terms of quality of life improvement.
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APPENDIX A: CONSENT TO PARTICIPATE IN RESEARCH FORM

74

75

APPENDIX B: DEMOGRAPHIC SURVEY QUESTIONS

Project Instruments for:
Effective Training Modalities to Teach the Use of Naloxone Nasal Spray
Demographic and Observation Collection Tool:
ID Code: ____/____/____
(FF) First 2 letters of participant first name
(MM) First 2 letters of mother’s first name
(YY) 2-digit year of birth

Do you consider yourself Hispanic/Latino?
Yes

No

Do you consider yourself? (check all that apply):
African- American

Gender Assigned at Birth:
Male
Female
Declined

American Indian/Alaskan Native

Current Gender Identity:
Male
Female
Transgender MTF Transgender FTM
Transgender – Unspecified
Declined

Asian/Pacific Islander
Caucasian
Hispanic/Latino
Unknown
Other _________
Decline
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APPENDIX C: PRIOR KNOWLEDGE SURVEY
Previous Knowledge Survey (Yes; N=No; D=Decline to answer):
1. Have you ever experienced an opioid overdose in the past? Circle: (Y/N/D)
1.a. If yes, was the most recent experience (checkmark the most recent event, only):
More than 12 months ago?
Within the previous 6-12 months?
Within the previous 0-6 months?
Decline to answer
2. Have you ever had a family member or close friend experience an opioid overdose?
Circle: (Y/N/D)
(Only answer questions 2.a, 2.b, and 2.b.1 if the answer to #2 was yes)
2.a. If yes to question #2, were there more than one situations with an opioid overdose? Circle: (Y/N/D)
2.b. If yes to question #2, how many times has a family member or close friend experienced an opioid
overdose? _____ (# or D)
2.b.1. What was the disposition of each opioid overdose situation? (in the event of multiple opioid
overdose situations mark each outcome listed with the number of times it occurred; i.e. if there were 2
incidents, the total should add to 2):
Individual revived _____ (# or D)
Individual deceased ____ (# or D)
3. Have you heard of naloxone or Narcan before? Circle: (Y/N/D)
(Only answer question 3.1 if the response to #3 is yes)
3.1. If yes, did you know naloxone/Narcan can reverse opioid overdoses? Circle: (Y/N/D)
4. Are you interested in learning how to use a medication to reverse an opioid overdose? Circle: (Y/N/D)
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APPENDIX D: WRITTEN EDUCATIONAL MATERIAL USED IN THE STUDY
Written Educational Material (used also for the video and face-to-face education):
How to Assemble and Use Naloxone Nasal Spray
Naloxone Assembly and Administration
1.
2.
3.
4.
5.
6.

Remove the colored caps on medicine vial and syringe barrel
Twist nasal atomizer onto tip of barrel.
Insert vial into barrel & gently turn until it stops. It is ready to use‡
Place assembled naloxone atomizer into one nostril
Press firmly on base of vial, spraying half into nostril
Repeat in the other nostril

Adapted from the public NMDOH – Hepatitis and Harm Reduction Program – “Overdose Prevention and Rescue Breathing in 20 -Minutes or Less” Curriculum, 2017
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APPENDIX E: OBSERVATION CHECKLIST

Participant Code:

__ __ / __ __ / __ __

Suit Drawn (circle): Spades

Hearts

Clubs

Diamonds

Observation 1 Checklist:
Assembly (0-1-2-3):
0 – none of the pieces attached together
1 – atomizer attached correctly to the barrel (but not medication vial)
2 - barrel and medication vial correctly attached (but not atomizer)
3 – all three pieces, atomizer, barrel, and medication vial attached correctly
Time: _______
Administration (0-1-2-3):
0 – not administered
1 – medication expressed in only one nostril;
2 - medication expressed orally
3 – medication expressed ½ in one nostril and ½ in the second nostril
Time: _______
Observation 2 Checklist (follow-up):
Assembly (0-1-2-3):
0 – none of the pieces attached together
1 – atomizer attached correctly to the barrel (but not medication vial)
2 - barrel and medication vial correctly attached (but not atomizer)
3 – all three pieces, atomizer, barrel, and medication vial attached correctly
Time: _______
Administration (0-1-2-3):
0 – not administered
1 – medication expressed in only one nostril;
2 - medication expressed orally
3 – medication expressed ½ in one nostril and ½ in the second nostril
Time: _______
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APPENDIX F: EXIT SURVEY
Exit Survey:
Participant Code:

__ __ / __ __ / __ __

*You may decline to answer any question by circling the “Decline” option, or stop the survey at any time.
1). Did you research or see material about naloxone during the time from the first appointment until today?
Circle one:

Yes

No

Decline

A). If yes to Question #1, was the information:
Circle all which apply:

Written

Video/Visual

Audio

Decline to answer

B). If yes to Question #1, approximately how much time did you spend reading/viewing information
about naloxone (in hours – round up to the nearest ½ hour): __________hours

Decline to answer

2). How did you feel going through the sessions? (or Decline to answer):

3). Do you believe information on naloxone is helpful?
Circle one:

Yes

No

Decline

A). Why or how? (or Decline to answer):

4). Use this space to write anything else you would like concerning this experience ? (or Decline to answer):
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APPENDIX G: SCRIPTS FOR EDUCATIONAL SESSIONS – FIRST SESSION
Scripts for researchers:
Do not read the bold portions to the subject
Spades: no educational materials
Thank you for participating in this research study.
Here are the three pieces of a device used to administer naloxone, which is a medication which can reverse
opioid overdoses. Please demonstrate assembling the device and how it should be administered on a person
(using the rescue mannequin) when I say “Start”. You will be timed while you demonstrate this. I cannot answer
questions during this portion of the study. START

Hearts: written instructions
Thank you for participating in this research study.
Here are written instructions showing and explaining how to assemble and administer naloxone, which is a
medication which can reverse opioid overdoses. You have 45 second to read through this educational material.
(after the 45 seconds) – remove the instructions and place the three pieces of the device in front of the
subject (barrel and medicine vial in the box, atomizer separate).
Here are the three pieces of the device. Please demonstrate assembling the device and how it should be
administered on a person (using the rescue mannequin) when I say “Start”. You will be timed while you
demonstrate this. I cannot answer questions during this portion of the study.
START

Clubs: Video
Thank you for participating in this research study.
Here are video instructions showing and explaining how to assemble and administer naloxone, which is a
medication which can reverse opioid overdoses.
(after the 45 seconds) – place the three pieces of the device in front of the subject (barrel and medicine
vial in the box, atomizer separate).
Here are the three pieces of the device. Please demonstrate assembling the device and how it should be
administered on a person (using the rescue mannequin) when I say “Start”. You will be timed while you
demonstrate this. I cannot answer questions during this portion of the study.
START

Diamonds: In-person
Thank you for participating in this research study.
I will show you how to assemble and administer naloxone, which is a medication which can reverse opioid
overdoses.
(after the 45 second demo) – place the three pieces of the device in front of the subject (barrel and
medicine vial in the box, atomizer separate).
Here are the three pieces of the device. Please demonstrate assembling the device and how it should be
administered on a person (using the rescue mannequin) when I say “Start”. You will be timed while you
demonstrate this. I cannot answer questions during this portion of the study.
START
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APPENDIX H: SCRIPT FOR EDUCATIONAL SESSION – SECOND SESSION
Script for researchers – Follow-up/Second Observation Session:
Do not read the bold portions to the subject
Thank you for participating in this research study.
Here are the three pieces of the device you were shown in the previous session. Please demonstrate assembling
the device and how it should be administered on a person (using the rescue mannequin) when I say “Start”. You
will be timed while you demonstrate this. I cannot answer questions during this portion of the session.
START
After the demonstration is complete/finished:
Please return to the check-in desk for the exit survey and to receive your Research Participation Form. If you
are interested in receiving the full educational session on overdose prevention and naloxone administration
simply ask at the desk. The educational session takes about 20 minutes to complete.
Thank you.

82

APPENDIX I: 20 MINUTE EDUCATIONAL CURRICULUM
Overdose Prevention and Rescue Breathing in 20 minutes or less
A. What causes an overdose (OD)
•
•
•
•
•

Toxic amount: too much of the substance; reduce amount and do tester shot
Mixing: effects are amplified; reduce amounts, inject first if mixing with alcohol
Tolerance: lowers during periods of non-use (i.e.: detox/jail/no money); reduce and do tester shot
Quality: varies in strength and purity; try to use known source and do tester shot
Using Alone: if something goes wrong – nobody to help; fix w/friend, unlocked door, and call someone trusted

B. How to recognize an OD
•
•

Over-amp: Stimulants (cocaine/speed) make the body speed up
Overdose: Heroin and other downers (alcohol/benzos) make the body slow
o Signs of OD: Unresponsive, unconscious, breathing slow/shallow (<12 breaths/min); pale, clammy, loss of color,
blue/gray (esp. lips/nails); loud/uneven snoring/gurgling; not breathing; faint/no pulse
o High vs OD: “the line”= UNRESPONSIVE

C. What to do if OD occurs
•
•

•
•

Stimulation: Call name, sternum rub
Call 911 - Good Samaritan 911 Law: protects against citation or arrest, except if another law is being broken
o Quiet the scene (or go to a quiet area), be calm and speak clearly, and do not argue
o Give exact address/location, person not breathing or turning blue
o There is no need to say: it is an overdose, give a name, or if drugs were involved
o Tell the paramedics everything known about the situation when they arrive
Use Naloxone
Perform Rescue Breathing = If they do not start breathing in 3 minutes, use a second dose of naloxone

D. Naloxone Administration
(using device with separate atomizer)
1. Remove the colored caps on medicine vial and syringe barrel
2. Insert vial into barrel & gently turn until it stops
3. Twist nasal atomizer onto tip of barrel. It is ready to use‡
4. Place assembled naloxone atomizer into one nostril
5. Press firmly on base of vial, spraying half into nostril
6. Repeat in other nostril
‡If an atomizer is not available (lost, missing, etc…), slowly drip the naloxone under the tongue
(using “all-in-one” intranasal device)
*
1. Remove device from blister pack
2. Place nozzle end into nostril
3. Press firmly on base of device, spraying medication into nostril
*Stay with the person as naloxone loses effect 30-90 minutes after administration.

*

E. Rescue Breathing
• Stimulation and Airway
1.
Check responsiveness. Ask, ”Are you okay?”, shake foot, use sternum rub
2.
Are they breathing? Look, listen and feel
3.
If no response, call 911
4.
Check for clear airway. If blocked, roll on side and use finger sweep to clear
•
Rescue Breathing
1.
Roll onto back, tilt head back and pinch nose
2.
Give 2 regular breaths
3.
Look, listen and feel
4.
If still not breathing give 1 breath every 5 seconds
5.
Continue until person revives or help arrives
6.
Once they start breathing, put them in the recovery position
•

F.

*Remember to keep breathing for them. Brain damage starts occurring 4 minutes after loss of oxygen.
Recovery Position

OD Myths – These do not work:
•
Slap or punch: may bruise or break nose/jaw
•
Put in cold water or use ice: makes the body cold, slow even more, and can lead to hypothermia
•
Use a lamp cord like a home-made defibrillator: can cause electric burns, irregular heart beat, or death
•
Inject with milk/saline/other substances: can cause the body to go into shock

Naloxone is available through pharmacies if you have Medicaid or insurance. Locations can be found through:
https://www.doseofrealitynm.com/
If you do not have Medicaid or insurance, or if you are enrolled in the Syringe Service Program, naloxone is available through the NMDOH
Public Health Offices and Community Partners. Locations can be found through: www.nmhivguide.org
Thanks to Rebecca Chavez (4-1-8), HRC http://www.harmreduction.org/article.php?list=type&type=72, and *Adapt Pharma (images). Revisions: by D. Zurlo and J. Murphy 9-12-17
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APPENDIX J: OBSERVATION FREQUENCY TABLES FOR TIME TO
DEMONSTRATE ASSEMBLY AND ADMINISTRATION
Observation 1 – Assembly Time

Valid

.00
19.00
20.00
21.00
22.00
23.00
24.00
25.00
26.00
27.00
29.00
30.00
31.00
32.00
33.00
34.00
35.00
36.00
37.00
38.00
40.00
41.00
42.00
44.00
45.00
47.00
50.00
51.00
52.00

Frequency Percent Valid Percent
2
2.1
2.2
2
2.1
2.2
3
3.2
3.2
2
2.1
2.2
1
1.1
1.1
3
3.2
3.2
1
1.1
1.1
1
1.1
1.1
1
1.1
1.1
1
1.1
1.1
3
3.2
3.2
5
5.3
5.4
4
4.3
4.3
3
3.2
3.2
2
2.1
2.2
2
2.1
2.2
3
3.2
3.2
2
2.1
2.2
3
3.2
3.2
3
3.2
3.2
3
3.2
3.2
2
2.1
2.2
2
2.1
2.2
1
1.1
1.1
2
2.1
2.2
1
1.1
1.1
3
3.2
3.2
1
1.1
1.1
1
1.1
1.1
84

Cumulative
Percent
2.2
4.3
7.5
9.7
10.8
14.0
15.1
16.1
17.2
18.3
21.5
26.9
31.2
34.4
36.6
38.7
41.9
44.1
47.3
50.5
53.8
55.9
58.1
59.1
61.3
62.4
65.6
66.7
67.7

53.00
57.00
58.00
60.00
61.00
70.00
71.00
75.00
76.00
86.00
89.00
99.00
100.00
112.00
117.00
120.00
125.00
130.00
136.00
152.00
156.00
186.00
234.00
235.00
298.00
346.00
Total
Missing System
Total

1
1
1
2
2
1
1
1
1
1
1
1
1
1
2
1
1
1
1
1
2
1
1
1
1
1
93
1
94

1.1
1.1
1.1
2.1
2.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
2.1
1.1
1.1
1.1
1.1
1.1
2.1
1.1
1.1
1.1
1.1
1.1
98.9
1.1
100.0

1.1
1.1
1.1
2.2
2.2
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
2.2
1.1
1.1
1.1
1.1
1.1
2.2
1.1
1.1
1.1
1.1
1.1
100.0

Observation 1 – Administration Time
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68.8
69.9
71.0
73.1
75.3
76.3
77.4
78.5
79.6
80.6
81.7
82.8
83.9
84.9
87.1
88.2
89.2
90.3
91.4
92.5
94.6
95.7
96.8
97.8
98.9
100.0

Valid 27.00
28.00
29.00
32.00
33.00
34.00
35.00
38.00
39.00
40.00
41.00
43.00
44.00
45.00
46.00
47.00
48.00
49.00
50.00
51.00
52.00
53.00
54.00
55.00
56.00
57.00
60.00
64.00
65.00
66.00
67.00
68.00
70.00

Frequency Percent Valid Percent
1
1.1
1.1
1
1.1
1.1
1
1.1
1.1
1
1.1
1.1
1
1.1
1.1
2
2.1
2.1
2
2.1
2.1
3
3.2
3.2
6
6.4
6.4
1
1.1
1.1
1
1.1
1.1
2
2.1
2.1
3
3.2
3.2
1
1.1
1.1
2
2.1
2.1
1
1.1
1.1
2
2.1
2.1
1
1.1
1.1
5
5.3
5.3
1
1.1
1.1
2
2.1
2.1
2
2.1
2.1
3
3.2
3.2
2
2.1
2.1
3
3.2
3.2
1
1.1
1.1
1
1.1
1.1
2
2.1
2.1
2
2.1
2.1
1
1.1
1.1
3
3.2
3.2
1
1.1
1.1
1
1.1
1.1
86

Cumulative
Percent
1.1
2.1
3.2
4.3
5.3
7.4
9.6
12.8
19.1
20.2
21.3
23.4
26.6
27.7
29.8
30.9
33.0
34.0
39.4
40.4
42.6
44.7
47.9
50.0
53.2
54.3
55.3
57.4
59.6
60.6
63.8
64.9
66.0

71.00
73.00
76.00
81.00
82.00
87.00
88.00
93.00
96.00
100.00
101.00
116.00
120.00
128.00
130.00
143.00
144.00
145.00
153.00
155.00
161.00
162.00
194.00
228.00
246.00
255.00
262.00
298.00
346.00
Total

1
1
1
1
1
2
1
1
1
1
1
1
1
1
1
1
2
1
2
1
1
1
1
1
1
1
1
1
1
94

1.1
1.1
1.1
1.1
1.1
2.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
2.1
1.1
2.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
100.0

1.1
1.1
1.1
1.1
1.1
2.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
2.1
1.1
2.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
100.0

Observation 2 – Assembly Time

87

67.0
68.1
69.1
70.2
71.3
73.4
74.5
75.5
76.6
77.7
78.7
79.8
80.9
81.9
83.0
84.0
86.2
87.2
89.4
90.4
91.5
92.6
93.6
94.7
95.7
96.8
97.9
98.9
100.0

Valid

17.00
18.00
19.00
20.00
22.00
23.00
24.00
25.00
26.00
27.00
28.00
29.00
30.00
31.00
32.00
33.00
34.00
35.00
36.00
37.00
38.00
40.00
41.00
42.00
43.00
44.00
46.00
47.00
49.00
50.00
58.00
60.00
61.00

Frequency Percent Valid Percent
3
3.2
3.3
3
3.2
3.3
1
1.1
1.1
3
3.2
3.3
5
5.3
5.6
2
2.1
2.2
1
1.1
1.1
3
3.2
3.3
3
3.2
3.3
1
1.1
1.1
4
4.3
4.4
3
3.2
3.3
3
3.2
3.3
3
3.2
3.3
3
3.2
3.3
1
1.1
1.1
2
2.1
2.2
3
3.2
3.3
2
2.1
2.2
2
2.1
2.2
6
6.4
6.7
5
5.3
5.6
2
2.1
2.2
1
1.1
1.1
1
1.1
1.1
1
1.1
1.1
1
1.1
1.1
1
1.1
1.1
1
1.1
1.1
3
3.2
3.3
3
3.2
3.3
1
1.1
1.1
1
1.1
1.1
88

Cumulative
Percent
3.3
6.7
7.8
11.1
16.7
18.9
20.0
23.3
26.7
27.8
32.2
35.6
38.9
42.2
45.6
46.7
48.9
52.2
54.4
56.7
63.3
68.9
71.1
72.2
73.3
74.4
75.6
76.7
77.8
81.1
84.4
85.6
86.7

66.00
69.00
70.00
75.00
78.00
79.00
93.00
121.00
123.00
133.00
163.00
175.00
Total
Missing System
Total

1
1
1
1
1
1
1
1
1
1
1
1
90
4
94

1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
95.7
4.3
100.0

1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
100.0

89

87.8
88.9
90.0
91.1
92.2
93.3
94.4
95.6
96.7
97.8
98.9
100.0

Observation 2 – Administration Time

Valid

23.00
24.00
26.00
27.00
28.00
29.00
30.00
31.00
32.00
33.00
34.00
35.00
37.00
38.00
39.00
40.00
41.00
42.00
43.00
44.00
45.00
46.00
47.00
48.00
50.00
51.00
52.00
53.00
56.00
57.00
65.00

Frequency Percent
1
1.1
2
2.1
2
2.1
1
1.1
2
2.1
3
3.2
2
2.1
1
1.1
1
1.1
2
2.1
1
1.1
1
1.1
3
3.2
2
2.1
3
3.2
1
1.1
4
4.3
5
5.3
3
3.2
2
2.1
2
2.1
3
3.2
2
2.1
3
3.2
2
2.1
1
1.1
5
5.3
3
3.2
1
1.1
3
3.2
2
2.1

Valid
Percent
1.1
2.2
2.2
1.1
2.2
3.3
2.2
1.1
1.1
2.2
1.1
1.1
3.3
2.2
3.3
1.1
4.4
5.6
3.3
2.2
2.2
3.3
2.2
3.3
2.2
1.1
5.6
3.3
1.1
3.3
2.2
90

Cumulative
Percent
1.1
3.3
5.6
6.7
8.9
12.2
14.4
15.6
16.7
18.9
20.0
21.1
24.4
26.7
30.0
31.1
35.6
41.1
44.4
46.7
48.9
52.2
54.4
57.8
60.0
61.1
66.7
70.0
71.1
74.4
76.7

68.00
70.00
71.00
73.00
79.00
80.00
82.00
83.00
90.00
92.00
93.00
102.00
104.00
123.00
134.00
138.00
152.00
163.00
192.00
Total
Missing System
Total

1
1
1
1
1
2
1
2
1
1
1
1
1
1
1
1
1
1
1
90
4
94

1.1
1.1
1.1
1.1
1.1
2.1
1.1
2.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
95.7
4.3
100.0

1.1
1.1
1.1
1.1
1.1
2.2
1.1
2.2
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
1.1
100.0

91

77.8
78.9
80.0
81.1
82.2
84.4
85.6
87.8
88.9
90.0
91.1
92.2
93.3
94.4
95.6
96.7
97.8
98.9
100.0

APPENDIX K: RESPONSES TO EXIT SURVEY OPEN-ENDED QUESTION –
“DO YOU BELIEVE INFORMATION ON NALOXONE IS HELPFUL?”
Participant Open-Ended Responses to the 2-part Exit Survey Question when the Initial
Response was “Yes”: Do you believe information on naloxone is helpful? Why or how?
(or Decline to answer):
Confused at first, as the device seemed hard to assemble.
First time anxious and made a mess and my guy probably died. Second time I knew what to do
and saved him no problem.
Positive.
There was minimal stress from either activity, but the initial un-familiarness with the device
would make it incredibly difficult to perform in a life-or-death situation.
The first time I was frustrated with the lack of instructions on the box and the 2nd time I just
did exactly what I did the first time.
I did not have a clue about the purpose of my first session. I did happen to break the vial. I did
tried to fill in the lack of information for the process.
I felt confused at first, but naloxone seemed easy to administer (if I did it right)
During the first session I was a little stressed out because I didn't know how to use or function
the device or medication.
The first time I felt anxious/nervous but afterwards I thought about this study for a few days.
The second time I felt confident.
1st session I was anxious and did it wrong. 2nd session was easier; more composed.
Excited - I found the study interesting.
I was overly concerned that I may have killed your dummy on session one.
Initially, confused because I thought I was in the group who had no instruction, however at the
end realized I was given the box w/instructions on it after completing administrating the
"naloxene." I decided this time to use only these instructions, not intuition and saw one piece
was not mentioned in them so attached it as I saw made sense to me.
I was very nervous the first time, but I felt less nervous and pressured the second time
In the first session I was nervous and took a while to assemble the object after I figured out
how it was done it seemed pretty easy. I'm glad I know have some experience in case of a real
situation.
The first session was a bit difficult because I didn't know what I was supposed to do. The first
attempt using the spray I know of tried to reason out how it would. After seeing how to use it I
found I was only one or two steps from a correct use of the spray. The second session I was
more prepared and had a better understanding of how to assemble and use the spray.
Nervous and confused. Instructions on package weren't very clear.
I felt this was highly useful and mostly everyone should learn how to do this. You can save a
person's life.
It felt strange not knowing what I was doing. Especially not being able to ask any questions, I
was a bit nervous.
I feel like I do not know what I was doing. I do not the product and because I couldn't ask
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questions about that I felt hopeless.
I felt confused the first time as to what went where and did not feel prepared. The second time
I felt more prepared and remembered what I did the previous time.
I felt anxious and nervous! It's really intimidating to be timed on a new task you know
absolutely nothing about. However, I took a breath to read the instructions on the box :)
fine, normal.
I felt uneasy administering the drug b/c I did not know if I correctly did it and could
potentially harm a person in the future.
It was a little strange, but I'm glad to have experienced this. The only other info I have attained
includes visual billboards. This was a great learning experiment because now I know about
how to administer naloxone.
Comfortable and confident.
I felt more confident during the second session about being able to administer the naloxone
treatment than in the first session. I think this was because the information from the first
session had time to sink in. I fumbled with the mechanism the second time for a moment, but
other than this I felt more confident during session two.
Fine. It was really easy. At first, I was a little scared I wouldn't remember anything but once I
was given it I remembered.
I felt silly for not being able to administer the device the 2nd time, but found the information
and demonstration helpful.
It was fun being a guinea pig (I've always wanted to participate in a study like this) Even
though this was for a class, I enjoyed it nonetheless.
easy, simple directions, satisfied.
I felt confident with what I was doing. I remembered to remove all the caps, but forgot to twist
the attachment until I heard a click.
I felt good going through it.
I was feeling a bit anxious during the first session. I feel like I didn't retain much information
that was handed to me, prior to attempting to set up the nasometer. I was not able to set it up
because of that. Although I looked up info online, I did not view info that would have helped
me to be more successful the second time around. I did feel better about it because I had seen
the equipment before.
I felt at easy and I was glad to go through learning how to administer the drug. It was a nice
way to be exposed to this drug and leave knowing more about it and how to help someone.
I felt kind of confused, but I think I eventually got it down.
I felt good, the first session was a bit nerve-wracking but the second was easier.
Nervous because I wanted to do the injection correctly and as fast as I could.
Worry because I did not do it the first time, so I am not sure what it was the correct way. I was
kind of confused from the beginning of the experiment even though I had the opportunity to
read the instructions in my first try, I think the idea of timing my reading made me feel a little
nervous, so I couldn't concentrate.
I felt more comfortable during the second session because I had time to search about naloxone
and how to apply it.
I wish I would have been able to use the instruction sheet as I performed the study. Or, if it
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could have been demonstrated - that would have been awesome! I felt frustrated because I
could not figure it out!
I felt a little confused on how to assemble device even after reading directions the first time.
After the first session I was confident I would remember the information, though doing it a
second time only a week after the first it was much more difficult to remember.
I felt rushed to know how to do this. I understand the reason for being timed now.
I felt pretty confident because it is a fairly simple device to assemble.
At first it was a little awkward because it was really quiet and they were watching us do the
task which kind of made it a little nerve wracking but the second time it wasn't too bad.
Because I remembered how to put the tool together and how to insert it which made the
session go quicker I actually enjoyed this experiment.
I felt like it is an easy to use device, don't know much about the actual medication but the
device was really easy to operate. I would certainly find it easy to use in a real-life situation.
I felt pretty good but would have felt much better and more confident if I saw the video at least
once more.
I decline to answer.
It was interesting to see how to assemble the device and know how to use it in times of
emergency.
I felt a little out of my comfort zone, but administering the naloxone was explained in a clear
manner, so I felt that it was simple to complete the task.
Relax and wasn't totally sure what it was what it is about it was fairly easy
I felt very confident going through the second session even without the video.
No problems. I was able to absorb and demonstrate the procedure with no complications. No
issue.
A little nervous about being able to retain the information and if I was going to be able to
follow the instructions the first time.
It was a lot easier than I expected. Although today I felt like I didn't screw it on tightly enough.
At times I wished like I could ask for confirmation.
Confident and prepared.
I felt good; pretty confident doing what was asked.
I was nervous the first time because I didn't know what to expect but the second time I felt
more confident.
Good, it was interesting that's why I spent time researching to see if this was the real deal,
because this could be awesome to prevent horrible things like overdosing.
I remembered how to administer it.
I felt a bit nervous, just because I didn't want to be wrong, but administration of naloxone is
fairly simple and the video covered everything I needed! I am glad to be more informed, and I
think I have gotten better at administering naloxone already.
I felt somewhat confident, however I would've felt better if I had feedback from the last
session.
I had a good feeling and I hope to help people that need on naloxone.
A little nervous.
I felt like I learned a lot. I had no idea this medicine was being given, so learning how to
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assemble made me feel helpful.
First I felt rushed and a little unsure. Second time was comfortable and felt more prepared.
I feel better and more prepared. I didn't even know the drug existed.
Okay, and confident enough to administer to someone if it was available at the moment.
Calm and collected, especially the second time through.
I was nervous administering the naloxone. It felt as if I were taking a test but more important
because of the thought of possibly giving that to a human that could be overdosing.
It was very easy and informative. It's something we need to have with us at all times
I thought it was interesting and not too difficult.
More nervous the second time - good experience - glad I know more about naloxone.
At first, I did not understand what the study was about. However, after I thought it was really
interesting.
I felt good; the second one it took me a second to remember, but once I remembered it was
simple to complete.
At ease, the assembly was pretty simple and I remembered the method of administering the
product.
At ease and confident after the demonstration.
I was nervous both sessions and I think I messed up a little on the second session. Overall this
was really helpful and I feel confident and comfortable administering naloxone to a person
Confident. Didn't know if I would remember, but wasn't nervous.
It took me longer to remember how to assemble the device, but once I remembered it was
easy!
Good, pretty simple. A little nervous for some reason.
They were quick, which was different from other studies I've been involved in.
Nervous because I wanted to do the injection correctly and as fast as I could.
I felt comfortable. Like there was no pressure or rush to perform the tasks.
Pressured because I was timed, I didn't want to do it wrong.
I felt more confident if I was in a situation here some overdosed I'd be able to administer
naloxone.
I felt like I did a good job. The way the sessions were designed/structured made me curious to
know more about what I was doing.
A little nervous but I feel like if I had to do this in real life I would be better prepared to
administer the naloxone.
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APPENDIX L: RESPONSE TO EXIT SURVEY QUESTION – “WHY OR HOW
DO YOU BELIEVE INFORMATION ON NALOXONE IS IMPORTANT”
Participant Open-Ended Responses to the Exit Survey Question: Why or how do you
believe information on naloxone is important?
Yes, because it may save a life.
It is a strange device. Better instructions would be good.
In our state, overdose of opiates is extremely high.
Giving greater awareness to overdose prevention techniques and medicines can help the
"herd immunity" of a community and combat bystander syndrome".
I don't know, what it is, I did not search it up.
I believe it needs maybe more simple words to follow the directions. I believe that in a
moment when you know is life or death. You should not have to stop and read, read again to
understand simple directions.
Any information/medication to help overdose is helpful and could save lives.
Yes, because it gives us more knowledge about how to use it or what it's meant for. It also
helps us have a more confident response.
To reverse an overdose. It's important to know just in case.
I didn't receive any info, but I'm sure it would.
Once people know about it - (medication) - it can save lives.
Directions that give info as if the preparer knows nothing is best for all - those who can skim
will (The box only says to remove lid…which on??).
New Mexico college students seem to be at risk for overdosing more so than other places (I
believe). Any prevention of a lost life is valuable information to have.
It can be helpful to know how to use it so you can help someone that may be going through
an overdose or be there to help someone who is likely to experience an overdose.
I feel I now know how to react better in a situation.
Although I don't think I will personally use a device such as this but it is still helpful to know
for those instances where anything may happen.
I believe it's helpful because naloxone helps with overdose, and if we are knowledgeable
about it and on how to use it we can help save someone's life.
When someone is in need for a rescue of this overdose, we know that there is something we
can fall back on.
Now knowing how to use naloxone to help someone maybe after I read about it a bit more I'll
know how I can use it in actual life.
Written information and hands on training.
I feel it is helpful because it could be used to save someone's life and I would be able to
identify features of an overdose.
Well I think I recall the people instructing this experiment that this is to administer to
someone which has an overdose and I would like to save someone's life if that was the case.
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to be prepared to help someone if ever a situation arose that demanded the administration of
Naloxone.
This information will teach the public to save lives.
The effects naloxone can have on preventing an overdose is/can be beneficial for future
situations. I feel like more information could be advertised/displayed/shown in other
mediums.
It can be an important drug in this age, and I see common knowledge of it as beneficial and
important.
I think it is important because opiate overdoses occur regularly and it is good to know that
there is a treatment to help combat it. It is also important to know how to administer the
treatment.
I had no idea what it was when I came in.
Learning how to administer the device…putting it together.
I say potentially because I don't know a whole lot about it. All I know is that it's administered
during an opioid overdose, and supposed to help the person and how can that not be helpful?
But if I knew more about naloxone, then yes. If it is helpful information.
In any situation, whether it's with a family member or friend, we will know how to administer
naloxone.
I learned what to do so if ever need it, I'll know what to do.
The nasometer could save someone's life, but I think it's really easy to make a mistake,
especially in stressful situations (just as I was doing).
There is a large opioid/drug use problem in New Mexico and naloxone can help people who
overdose. I am in nursing school so learning about this has been very interesting and useful.
You never know when someone can overdose, and at least knowing basic information is
better than knowing nothing.
Yes, because it could be helpful in future lives.
Knowing what situations it can be beneficial for.
I believe it is helpful because if you get into a situation where you have to apply naloxone you
are informed and know how to administer it.
It can be useful, so that I will know how to administer. I also am working with kids all the time
and it would be a great skill to have.
I do not imbibe myself or affiliate with others who do drugs.
If knowing enough info on administering it can save lives, it is clearly helpful.
I can reverse and overdose, therefore it is life saving and is very helpful, especially living in
Albuquerque.
Yes because it tells how it can prevent people from overdosing.
Because of all the climate in which we live, I mean political and social. There is a big
movement to legalize marihuana all over the country. What's next? Cocaine?
It is critical to saving lives, especially in a time when opioid overdoses are so prominent
I decline to answer.
You never know what someone is going through, so it is good to know how to help someone
97

who overdoses.
Information on naloxone is important because it gives people a tool to be able to reverse
opioid overdoses.
Yes, because I know how administrate the naloxone.
I have family and friends who partake in substances for recreation and it makes me more
comfortable knowing I can help them if need be.
It can help save a life in the right situation.
To help people with opioid overdoses.
It's good to know to be able to administer if a friend or family member needs it.
It could help people. But I have no use for it.
Depending on situations there can be an instance when naloxone is needed to help someone.
If everyone knowns how to use it and maybe have one it could be helpful in frightening
situations.
It is good to know in case of an emergency.
If the general population can be more educated on administration of life-saving drugs, there
would be much less concern that people would be unprepared in case of an overdose! I had
never heard of naloxone before this study.
Any medication that people try to sell over the counter should have a lot of information for
the general public. Being a community Health major, I learned that the community isn't as
educated as we assume.
I hope to be useful for people that need help :)
Because it seems like an easy way to prevent overdose.
I believe it's helpful because one can never know when there will be a situation naloxone may
be needed to be given to someone. So having information can help save someone.
I think I would like to see the video one more time, but the information was enough for this
experiment.
It's good to have for emergencies even if no one in the household takes opioids recreationally.
Because it keeps friends, relatives, and acquaintances aware of possible interventions if
someone they know is struggling with abuse and possible ways to help them.
It is helpful for people to be aware of possible overdose and know how to counter the effects.
Hopefully if they are taking opioids or heroin or know people closely who are, that they have
some on hand.
This is part of awareness of different medications that are available or could be available.
It can stop overdose, that's something we all should try to stop.
If I was in a situation where someone was experiencing an overdose I would want to know
how to help them.
It would benefit many people who are faced w/someone overdosing.
The information on naloxone is helpful in helping stop an overdose.
I have a family member who struggles w/ opioid abuse so if I am around her I can administer
this and potentially save her life. Especially since within the past few days since she told the
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family of her struggle w/ the drugs.
It's important to know what is out there to possibly save lives.
It is a lifesaving procedure that I think is as important as CPR or mouth to mouth saving
procedures.
yes, it is helpful because now I know the proper way to administer naloxone.
Although I'm not sure where I would acquire naloxone, but if it were present in a situation it is
needed, it is good I know how.
Saving People! Always awesome :)
I honestly have done zero research.
I've worked in a few different care settings (ARCA, Mesilla Valley Hospital) so it's always
interesting to learn new care/med stuff.
Naloxone can help save a life of a person on opiates.
Because there may come a time in which I might be in a situation where the information on
naloxone may be helpful.
It is helpful because now I know I could help someone in the event that I am ever in the
situation where I needed too.
Because it would be helpful to know in the real world how to use it.
Well I do know that it is used on someone who is experiencing an overdose of opiates.
Because you can help prevent overdosing with this information. Maybe not prevent
overdosing per say but help counter the affects of it.
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APPENDIX M: RESPONSES TO EXIT SURVEY QUESTION – “USE THIS
SPAVE TO WRITE ANYTHING ELSE YOU WOULD LIKE CONCERNING
THIS EXPERIENCE.”
Participant Open-Ended Responses to the Exit Survey Question: “Use this space to write
anything else you would like concerning this experience. (or Decline to answer)?”
Nothing Else!
In an actual emergency, most people will fail to assemble and administer the medicine quickly
and effectively.
I thought this was a fabulous research study. Gave me confidence w/the administration of
naloxone in case I ever had to administer the drug.
Not knowing the response time required to prevent the overdose of someone makes the
participants self-perception of their performance completely uncontrollable.
This was a very interesting experience, but I felt like administering naloxone was almost selfexplanatory.
Very cool experience, good to know these types of things in the case of an emergency. I think
most to all people should learn this info.
I'm very interested to learn what you are really studying. Because I'm sure it's a little more
complicated than it's been made to seem.
It would be helpful to learn how to use it properly.
I hope I did better the 2nd go around. My only concern is that this will save the lives of those
who do not care. Will there be a certain # of times to be used on one person…or
hundreds…or thousands??
I believe I was supposed to eliminate variables to this research and that is why I did not
research between my two surveys.
I feel like it was very helpful because it helped me realize how little I knew about overdose
prevention.
To understand how to properly use naloxone.
I want to know why are you doing this survey and how this will help you decide what to do to
avoid overdoses.
I would like more explanation prior as to what naloxone is and it's affects. It would have also
been nice to be able to apply it/see it happen in real life and be tested.
I like how organized everything was and the way in which confirmation emails were sent out. I
knew everywhere I needed to be and felt confident by being part of the study.
The people are nice and were flexible with my forgetting the appointment.
Thank you! Very Helpful!
I don't have anything else to say other than it was fun and interesting experience. Good luck
on your dissertation! :) Glad to help! :)
I feel that the time it took to complete will help people remember better, at least it did for
me.
I feel that we need to be as informed about opium overdoses as possible. I am a father of 3
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and would certainly like to be as informed about it as can be. Thank you for doing this. I
appreciate your efforts to help the community.
I thought the video was the most effective way to learn because you have the visual and the
audio.
Like I said, the administration of the naloxone was out of my comfort zone, but the team
made me feel comfortable, and everything about the study was very straightforward and
useful.
I had no concerns. I enjoyed the study.
This is a great study and can lead to many improvements in this spectrum.
The audio on the video is terrible.
This was an interesting experience, and everyone was very friendly. I hope you get everything
you need out of this!
Administering the naloxone was easy and efficient.
Make this drug, medication, or whatever it's called, aware to everyone, like at orientation.
This was interesting!
I hope this test will be helpful for people.
I will be buying naloxone - just in case.
I found it fun taking part in an experiment. Especially one that I feel is important and helpful
for saving people.
Very informative.
Although I agree this is very helpful, I do wish we could also focus on prevention of drugs that
are harmful in the first place.
I think there should be more information about overdosing and what you should do if you are
in a situation where someone is overdosing given in a high school health classes because it is
valuable to be knowledgeable about these sorts of situations.
I was nervous on the second session because I really didn't want to mess up in the process.
Also, I like that an explanation of naloxone was not written because it forced me to do some
research. During the first session I was clueless and worried that there was no definition
about naloxone.
Nothing else to say :)
Not sure if this is relevant (since I did probably just "okay" with the second trial) but I do have
a lot of experience using different types of medical equipment in my personal life (because of
cystic fibrosis medication) so I don't know if that in any way influences my ability to retain
medication info.
Good experience.
I think it was fun being in a research study!
The instructions were clear to understand and easy to follow, making the experience easier. If
I had to do this in real life, I feel like I could do it.
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